Updated on 2024/11/27

Information

 

写真a

 
TSUCHIHASHI KENJI
 
Organization
Kyushu University Hospital Hematology, Oncology & Cardiovascular medicine Assistant Professor
School of Medicine Department of Medicine（Concurrent）
Title
Assistant Professor
Tel
0926425228
Profile
[診療] 腫瘍内科医として、外科、内科、放射線科、その他各専門科と協力・連携をとりながら、消化器がん、骨軟部腫瘍、甲状腺がん、原発不明がん、その他希少がんなど、幅広いがん腫の治療に携わっている。臨床試験、ゲノム検査に基づいた治療・臨床試験など新規治療法を積極的に取り入れ、また、全国の医療機関とも連携をとりながら、患者さんに様々な治療選択肢を提案できるように努めている。がんに伴う身体的・精神的苦痛、また様々な併存症についても、各専門家と連携しながら診療にあたり、トータルケアを行うことを目標としている。院内だけでなく、九州地域における充実した希少がん診療体制の確立を目指し、院内外で活動している。九州大学病院 希少がんセンター・希少がんホットライン・MASTERKEYプロジェクトに関わっている。 [研究] 新規治療開発を目指し、全国の臨床試験グループに参加している。WJOG消化器グループ、JCOG食道グループ、JCOG骨軟部グループに所属している。 より最適で安全な日常臨床医療に貢献できるように、同じグループの病院などと連携し臨床研究を行っている。 基礎研究では、がんの未知の病態解明や新規治療開発を目指し、大学院生と共に研究に取り組んでいる。希少がんの治療開発にも力を入れている。 [教育] 医学部生の腫瘍内科での臨床実習を担当している。大学院では、シグナル伝達とがん遺伝子、支持療法、がんと栄養の講義を担当している。日本臨床腫瘍学会認定がん薬物療法専門医取得を目指す医師と日常臨床を通じて議論をすることで教育に携わっている。大学院生と一緒に基礎研究に取り組むことで、研究の助言、指導を行っている。
External link

Degree

  • Ph.D.

Research History

  • 聖路加国際病院（初期臨床研修）

    聖路加国際病院（初期臨床研修）

  • 慶應義塾大学医学部先端医科学研究所遺伝子制御研究部門（共同研究員・准訪問研究員）

Research Interests・Research Keywords

  • Research theme：Elucidation of the underlying mechanism of tumor immune escape

    Keyword：Tumor immunology

    Research period： 2022.4

  • Research theme：Elucidation of immune-escape system of cancer by epitranscriptome

    Keyword：epitranscriptome, immun-escape system, cancer

    Research period： 2020.4 - 2022.3

  • Research theme：Elucidation of underlying mechanisms of tumorigenesis and development of new therapy in rare cancer

    Keyword：rare cancer

    Research period： 2020.4

  • Research theme：The exploration for the role of glutamic acid in xCT-dependent cancer stem cell

    Keyword：xCT, glutamic acid, cancer stem cell

    Research period： 2018.4 - 2020.3

  • Research theme：Development of therapeutic strategy regulating the resistance for oxidative stress in malignat glioma

    Keyword：oxidative stress, glioma

    Research period： 2016.4 - 2018.3

Awards

  • がん研究助成金　入賞

    2017.1   福岡県すこやか健康事業団  

Papers

  • Epithelioid hemangioendothelioma-its history, clinical features, molecular biology and current therapy Invited Reviewed International journal

    Kenji Tsuchihashi, Eishi Baba

    Jpn J Clin Oncol   2024.3

    　More details

    Language：Japanese   Publishing type：Research paper (scientific journal)  

  • Phase II Trial of Nivolumab in Metastatic Rare Cancer with dMMR or MSI-H and Relation with Immune Phenotypic Analysis (the ROCK Trial) Reviewed International journal

    Hitomi S Okuma, Keisuke Watanabe , @Kenji Tsuchihashi, Ryunosuke Machida, Ryo Sadachi, Akihiro Hirakawa, Hiroshi Ariyama, Masashi Kanai, Masahisa Kamikura, Kenta Anjo, Akari Hiramitsu, Shigeki Sekine, Natsuko Okita, Hiroyuki Mano, Hiroyoshi Nishikawa, Kenichi Nakamura, Kan Yonemori

    Clin Cancer Res   2023.12

    　More details

    Language：Japanese   Publishing type：Research paper (scientific journal)  

  • Survival outcomes including salvage therapy of adult head and neck para-meningeal rhabdomyosarcoma: a multicenter retrospective study from Japan Reviewed International journal

    Kenji Tsuchihashi, Mamoru Ito, Shuji Arita, Hitoshi Kusaba, Wataru Kusano, Takashi Matsumura, Takafumi Kitazono, Shohei Ueno, Ryosuke Taguchi, Tomoyasu Yoshihiro, Yasuhiro Doi, Kohei Arimizu, Hirofumi Ohmura, Tatsuhiro Kajitani, Kenta Nio, Michitaka Nakano 1, Kotoe Oshima, Shingo Tamura, Tsuyoshi Shirakawa, Hozumi Shimokawa, Keita Uchino, Fumiyasu Hanamura, Yuta Okumura, Masato Komoda, Taichi Isobe, Hiroshi Ariyama, Taito Esaki, Kazuki Hashimoto, Noritaka Komune, Mioko Matsuo, Keiji Matsumoto, Kaori Asai, Tadamasa Yoshitake, Hidetaka Yamamoto, Yoshinao Oda, Koichi Akashi, Eishi Baba

    BMC Cancer   2023.10

    　More details

    Language：Japanese   Publishing type：Research paper (scientific journal)  

  • Presence of spontaneous epithelial-mesenchymal plasticity in esophageal cancer. Reviewed International journal

    Tsuchihashi K, Hirata Y, Yamasaki J, Suina K, Tanoue K, Yae T, Masuda K, Baba E, Akashi K, Kitagawa Y, Saya H, Nagano O.

    Biochem Biophys Rep   30   101246   2022.3

    　More details

    Language：Japanese   Publishing type：Research paper (scientific journal)  

  • Eribulin as a first-line treatment for soft tissue sarcoma patients with contraindications for doxorubicin. Reviewed International journal

    Tsuchihashi K, Kusaba H, Yoshihiro T, Fujiwara T, Setsu N, Endo M, Matsumoto Y, Imajima T, Shinohara Y, Ito M, Yamaga S, Tanoue K, Arimizu K, Ohmura H, Hanamura F, Yamaguchi K, Isobe T, Ariyama H, Nakashima Y, Akashi K, Baba E.

    Sci Rep.   10   20896   2020.12

    　More details

    Language：Japanese   Publishing type：Research paper (scientific journal)  

  • The EGF Receptor Promotes the Malignant Potential of Glioma by Regulating Amino Acid Transport System xc(-). Invited Reviewed International journal

    Tsuchihashi K, Okazaki S, Ohmura M, Ishikawa M, Sampetrean O, Onishi N, Wakimoto H, Yoshikawa M, Seishima R, Iwasaki Y, Morikawa T, Abe S, Takao A, Shimizu M, Masuko T, Nagane M, Furnari FB, Akiyama T, Suematsu M, Baba E, Akashi K, Saya H, Nagano O.

    Cancer Res   2016.5

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

  • xCT inhibition depletes CD44v-expressing tumor cells that are resistant to EGFR-targeted therapy in head and neck squamous cell carcinoma. Invited Reviewed International journal

    Yoshikawa M, Tsuchihashi K, Ishimoto T, Yae T, Motohara T, Sugihara E, Onishi N, Masuko T, Yoshizawa K, Kawashiri S, Mukai M, Asoda S, Kawana H, Nakagawa T, Saya H, Nagano O.

    Cancer Res   2013.5

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

  • Alternative splicing of CD44 mRNA by ESRP1 enhances lung colonization of metastatic cancer cell. Invited Reviewed International journal

    Yae T, Tsuchihashi K, Ishimoto T, Motohara T, Yoshikawa M, Yoshida GJ, Wada T, Masuko T, Mogushi K, Tanaka H, Osawa T, Kanki Y, Minami T, Aburatani H, Ohmura M, Kubo A, Suematsu M, Takahashi K, Saya H, Nagano O.

    Nat Commun   2012.6

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

  • Spatial dynamics of CD39<SUP>+</SUP>CD8<SUP>+</SUP> exhausted T cell reveal tertiary lymphoid structures-mediated response to PD-1 blockade in esophageal cancer

    Tanoue, K; Ohmura, H; Uehara, K; Ito, M; Yamaguchi, K; Tsuchihashi, K; Shinohara, Y; Lu, P; Tamura, S; Shimokawa, H; Isobe, T; Ariyama, H; Shibata, Y; Tanaka, R; Kusaba, H; Esaki, T; Mitsugi, K; Kiyozawa, D; Iwasaki, T; Yamamoto, H; Oda, Y; Akashi, K; Baba, E

    NATURE COMMUNICATIONS   15 ( 1 )   9033   2024.10   （ eISSN:2041-1723 ）

    　More details

    Language：English   Publisher：Nature Communications  

    Despite the success of immune checkpoint blockade (ICB) therapy for esophageal squamous cell cancer, the key immune cell populations that affect ICB efficacy remain unclear. Here, imaging mass cytometry of tumor tissues from ICB-treated patients identifies a distinct cell population of CD39+PD-1+CD8+ T cells, specifically the TCF1+ subset, precursor exhausted T (CD39+ Tpex) cells, which positively correlate with ICB benefit. CD39+ Tpex cells are predominantly in the stroma, while differentiated CD39+ exhausted T cells are abundantly and proximally within the parenchyma. Notably, CD39+ Tpex cells are concentrated within and around tertiary lymphoid structure (TLS). Accordingly, tumors harboring TLSs have more of these cells in tumor areas than tumors lacking TLSs, suggesting Tpex cell recruitment from TLSs to tumors. In addition, circulating CD39+ Tpex cells are also increased in responders following ICB therapy. Our findings show that this unique subpopulation of CD39+PD-1+CD8+ T cells is crucial for ICB benefit, and suggest a key role in TLS-mediated immune responses against tumors.

    DOI： 10.1038/s41467-024-53262-w

    Web of Science

    Scopus

    PubMed

  • Treatment of malignant primary cardiac tumors requires attention to cardiovascular complications: a single-center, retrospective study

    Furukawa, K; Ohmura, H; Moriyama, S; Uehara, K; Ito, M; Tsuchihashi, K; Isobe, T; Ariyama, H; Fukata, M; Kusaba, H; Shiose, A; Akashi, K; Baba, E

    JAPANESE JOURNAL OF CLINICAL ONCOLOGY   2024.10   （ ISSN:0368-2811 eISSN:1465-3621 ）

    　More details

  • Effectiveness and safety of primary prophylaxis with G-CSF during chemotherapy for invasive breast cancer: a systematic review and meta-analysis from Clinical Practice Guidelines for the Use of G-CSF 2022

    Nozawa, K; Ozaki, Y; Yoshinami, T; Yokoe, T; Nishio, H; Tsuchihashi, K; Ichihara, E; Miura, Y; Endo, M; Yano, S; Maruyama, D; Susumu, N; Takekuma, M; Motohashi, T; Ito, M; Baba, E; Ochi, N; Kubo, T; Uchino, K; Kimura, T; Kamiyama, Y; Nakao, S; Tamura, S; Nishimoto, H; Kato, Y; Sato, A; Takano, T

    INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY   29 ( 8 )   1074 - 1080   2024.8   （ ISSN:1341-9625 eISSN:1437-7772 ）

    　More details

    Language：English   Publisher：International Journal of Clinical Oncology  

    Introduction: Chemotherapy for breast cancer can cause neutropenia, increasing the risk of febrile neutropenia (FN) and serious infections. The use of granulocyte colony-stimulating factors (G-CSF) as primary prophylaxis has been explored to mitigate these risks. To evaluate the efficacy and safety of primary G-CSF prophylaxis in patients with invasive breast cancer undergoing chemotherapy. Methods: A systematic literature review was conducted according to the “Minds Handbook for Clinical Practice Guideline Development” using PubMed, Ichushi-Web, and the Cochrane Library databases. Randomized controlled trials (RCTs) and cohort studies assessing using G-CSF as primary prophylaxis in invasive breast cancer were included. The primary outcomes were overall survival (OS) and FN incidence. Meta-analyses were performed for outcomes with sufficient data. Results: Eight RCTs were included in the qualitative analysis, and five RCTs were meta-analyzed for FN incidence. The meta-analysis showed a significant reduction in FN incidence with primary G-CSF prophylaxis (risk difference [RD] = 0.22, 95% CI: 0.01–0.43, p = 0.04). Evidence for improvement in OS with G-CSF was inconclusive. Four RCTs suggested a tendency for increased pain with G-CSF, but statistical significance was not reported. Conclusions: Primary prophylactic use of G-CSF is strongly recommended for breast cancer patients undergoing chemotherapy, as it has been shown to reduce the incidence of FN. While the impact on OS is unclear, the benefits of reducing FN are considered to outweigh the potential harm of increased pain.

    DOI： 10.1007/s10147-024-02570-8

    Web of Science

    Scopus

    PubMed

  • Primary prophylaxis with G-CSF for patients with non-round cell soft tissue sarcomas: a systematic review for the Clinical Practice Guidelines for the Use of G-CSF 2022 of the Japan Society of Clinical Oncology(タイトル和訳中)

    Hirose Takeshi, Ito Mamoru, Tsuchihashi Kenji, Ozaki Yukinori, Nishio Hiroshi, Ichihara Eiki, Miura Yuji, Yano Shingo, Maruyama Dai, Yoshinami Tetsuhiro, Susumu Nobuyuki, Takekuma Munetaka, Motohashi Takashi, Baba Eishi, Ochi Nobuaki, Kubo Toshio, Uchino Keita, Kimura Takahiro, Kamiyama Yutaro, Nakao Shinji, Tamura Shinobu, Nishimoto Hitomi, Kato Yasuhisa, Sato Atsushi, Takano Toshimi, Endo Makoto

    International Journal of Clinical Oncology   29 ( 8 )   1067 - 1073   2024.8   （ ISSN:1341-9625 ）

    　More details

    Language：English   Publisher：シュプリンガー・ジャパン(株)  

  • Effectiveness and safety of primary prophylaxis with G-CSF for patients with Ewing sarcomas: a systematic review for the Clinical Practice Guidelines for the Use of G-CSF 2022 of the Japan Society of Clinical Oncology(タイトル和訳中)

    Hirose Takeshi, Ito Mamoru, Tsuchihashi Kenji, Ozaki Yukinori, Nishio Hiroshi, Ichihara Eiki, Miura Yuji, Yano Shingo, Maruyama Dai, Yoshinami Tetsuhiro, Susumu Nobuyuki, Takekuma Munetaka, Motohashi Takashi, Baba Eishi, Ochi Nobuaki, Kubo Toshio, Uchino Keita, Kimura Takahiro, Kamiyama Yutaro, Nakao Shinji, Tamura Shinobu, Nishimoto Hitomi, Kato Yasuhisa, Sato Atsushi, Takano Toshimi, Endo Makoto

    International Journal of Clinical Oncology   29 ( 8 )   1081 - 1087   2024.8   （ ISSN:1341-9625 ）

    　More details

    Language：English   Publisher：シュプリンガー・ジャパン(株)  

  • Effectiveness and safety of primary prophylaxis with G-CSF during chemotherapy for invasive breast cancer: a systematic review and meta-analysis from Clinical Practice Guidelines for the Use of G-CSF 2022(タイトル和訳中)

    Nozawa Kazuki, Ozaki Yukinori, Yoshinami Tetsuhiro, Yokoe Takamichi, Nishio Hiroshi, Tsuchihashi Kenji, Ichihara Eiki, Miura Yuji, Endo Makoto, Yano Shingo, Maruyama Dai, Susumu Nobuyuki, Takekuma Munetaka, Motohashi Takashi, Ito Mamoru, Baba Eishi, Ochi Nobuaki, Kubo Toshio, Uchino Keita, Kimura Takahiro, Kamiyama Yutaro, Nakao Shinji, Tamura Shinobu, Nishimoto Hitomi, Kato Yasuhisa, Sato Atsushi, Takano Toshimi

    International Journal of Clinical Oncology   29 ( 8 )   1074 - 1080   2024.8   （ ISSN:1341-9625 ）

    　More details

    Language：English   Publisher：シュプリンガー・ジャパン(株)  

  • Effectiveness and safety of granulocyte colony-stimulating factor priming regimen for acute myeloid leukemia: A systematic review and meta-analysis of the Clinical Practice Guideline for the use of G-CSF 2022 from the Japan Society of Clinical Oncology(タイトル和訳中)

    Najima Yuho, Maeda Tomoya, Kamiyama Yutaro, Nakao Shinji, Ozaki Yukinori, Nishio Hiroshi, Tsuchihashi Kenji, Ichihara Eiki, Miumra Yuji, Endo Makoto, Maruyama Dai, Yoshinami Tetsuhiro, Susumu Nobuyuki, Takekuma Munetaka, Motohashi Takashi, Ito Mamoru, Baba Eishi, Ochi Nobuaki, Kubo Toshio, Uchino Keita, Kimura Takahiro, Tamura Shinobu, Nishimoto Hitomi, Kato Yasuhisa, Sato Atsushi, Takano Toshimi, Yano Shingo

    International Journal of Clinical Oncology   29 ( 7 )   899 - 910   2024.7   （ ISSN:1341-9625 ）

    　More details

    Language：English   Publisher：シュプリンガー・ジャパン(株)  

  • Effectiveness and safety of primary prophylaxis with G-CSF for patients with Ewing sarcomas: a systematic review for the Clinical Practice Guidelines for the Use of G-CSF 2022 of the Japan Society of Clinical Oncology

    Hirose, T; Ito, M; Tsuchihashi, K; Ozaki, Y; Nishio, H; Ichihara, E; Miura, Y; Yano, S; Maruyama, D; Yoshinami, T; Susumu, N; Takekuma, M; Motohashi, T; Baba, E; Ochi, N; Kubo, T; Uchino, K; Kimura, T; Kamiyama, Y; Nakao, S; Tamura, S; Nishimoto, H; Kato, Y; Sato, A; Takano, T; Endo, M

    INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY   29 ( 8 )   1081 - 1087   2024.6   （ ISSN:1341-9625 eISSN:1437-7772 ）

    　More details

    Language：English   Publisher：International Journal of Clinical Oncology  

    Background: Multidrug chemotherapy for Ewing sarcoma can lead to severe myelosuppression. We proposed two clinical questions (CQ): CQ #1, “Does primary prophylaxis with G-CSF benefit chemotherapy for Ewing sarcoma?” and CQ #2, “Does G-CSF-based intensified chemotherapy improve Ewing sarcoma treatment outcomes?”. Methods: A comprehensive literature search was conducted in PubMed, Cochrane Library, and Ichushi web databases, including English and Japanese articles published from 1990 to 2019. Two reviewers assessed the extracted papers and analyzed overall survival (OS), febrile neutropenia (FN) incidence, infection-related mortality, quality of life (QOL), and pain. Results: Twenty-five English and five Japanese articles were identified for CQ #1. After screening, a cohort study of vincristine, ifosfamide, doxorubicin, and etoposide chemotherapy with 851 patients was selected. Incidence of FN was 60.8% with G-CSF and 65.8% without; statistical tests were not conducted. Data on OS, infection-related mortality, QOL, or pain was unavailable. Consequently, CQ #1 was redefined as a future research question. As for CQ #2, we found two English and five Japanese papers, of which one high-quality randomized controlled trial on G-CSF use in intensified chemotherapy was included. This trial showed trends toward lower mortality and a significant increase in event-free survival for 2-week interval regimen with the G-CSF primary prophylactic use compared with 3-week interval. Conclusion: This review indicated that G-CSF’s efficacy as primary prophylaxis in Ewing sarcoma, except in children, is uncertain despite its common use. This review tentatively endorses intensified chemotherapy with G-CSF primary prophylaxis for Ewing sarcoma.

    DOI： 10.1007/s10147-024-02572-6

    Web of Science

    Scopus

    PubMed

  • Primary prophylaxis with G-CSF for patients with non-round cell soft tissue sarcomas: a systematic review for the Clinical Practice Guidelines for the Use of G-CSF 2022 of the Japan Society of Clinical Oncology

    Hirose, T; Ito, M; Tsuchihashi, K; Ozaki, Y; Nishio, H; Ichihara, E; Miura, Y; Yano, S; Maruyama, D; Yoshinami, T; Susumu, N; Takekuma, M; Motohashi, T; Baba, E; Ochi, N; Kubo, T; Uchino, K; Kimura, T; Kamiyama, Y; Nakao, S; Tamura, S; Nishimoto, H; Kato, Y; Sato, A; Takano, T; Endo, M

    INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY   29 ( 8 )   1067 - 1073   2024.6   （ ISSN:1341-9625 eISSN:1437-7772 ）

    　More details

    Language：English   Publisher：International Journal of Clinical Oncology  

    Background: Granulocyte colony-stimulating factor (G-CSF) is an essential supportive agent for chemotherapy-induced severe myelosuppression. We proposed two clinical questions (CQ): CQ #1, “Does primary prophylaxis with G-CSF benefit chemotherapy for non-round cell soft tissue sarcoma (NRC-STS)?” and CQ #2, “Does G-CSF-based intensified chemotherapy improve NRC-STS treatment outcomes?” for the Clinical Practice Guidelines for the Use of G-CSF 2022 of the Japan Society of Clinical Oncology. Methods: A literature search was performed on the primary prophylactic use of G-CSF for NRC-STSs. Two reviewers assessed the extracted papers and analyzed overall survival, incidence of febrile neutropenia, infection-related mortality, quality of life, and pain. Results: Eighty-one and 154 articles were extracted from the literature search for CQs #1 and #2, respectively. After the first and second screening, one and two articles were included in the final evaluation, respectively. Only some studies have addressed these two clinical questions through a literature review. Conclusion: The clinical questions were converted to future research questions because of insufficient available data. The statements were proposed: “The benefit of primary G-CSF prophylaxis is not clear in NRC-STS” and “The benefit of intensified chemotherapy with primary G-CSF prophylaxis is not clear in NRC-STSs.” G-CSF is often administered as primary prophylaxis when chemotherapy with severe myelosuppression is administered. However, its effectiveness and safety are yet to be scientifically proven.

    DOI： 10.1007/s10147-024-02569-1

    Web of Science

    Scopus

    PubMed

  • Integrated analysis of two phase 2 trials of nivolumab in metastatic rare solid cancer with dMMR or pMMR (MASTER KEY sub-studies: ROCK and ROLL trial).

    Kanai, M; Okuma, HS; Tsuchihashi, K; Machida, R; Sadachi, R; Hirakawa, A; Kamikura, M; Anjo, K; Sekine, S; Okita, NT; Nakamura, K; Yonemori, K

    JOURNAL OF CLINICAL ONCOLOGY   42 ( 16 )   2024.6   （ ISSN:0732-183X eISSN:1527-7755 ）

    　More details

  • Comparison between a single dose of PEG G-CSF and multiple doses of non-PEG G-CSF: a systematic review and meta-analysis from Clinical Practice Guidelines for the use of G-CSF 2022

    Yoshinami, T; Nozawa, K; Yokoe, T; Ozaki, Y; Nishio, H; Tsuchihashi, K; Ichihara, E; Miura, Y; Endo, M; Yano, S; Maruyama, D; Susumu, N; Takekuma, M; Motohashi, T; Ito, M; Baba, E; Ochi, N; Kubo, T; Uchino, K; Kimura, T; Kamiyama, Y; Nakao, S; Tamura, S; Nishimoto, H; Kato, Y; Sato, A; Takano, T

    INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY   29 ( 6 )   681 - 688   2024.6   （ ISSN:1341-9625 eISSN:1437-7772 ）

    　More details

    Language：English   Publisher：International Journal of Clinical Oncology  

    Backgroud: Granulocyte colony-stimulating factor (G-CSF) is widely used for the primary prophylaxis of febrile neutropenia (FN). Two types of G-CSF are available in Japan, namely G-CSF chemically bound to polyethylene glycol (PEG G-CSF), which provides long-lasting effects with a single dose, and non-polyethylene glycol-bound G-CSF (non-PEG G-CSF), which must be sequentially administrated for several days. Methods: This current study investigated the utility of these treatments for the primary prophylaxis of FN through a systematic review of the literature. A detailed literature search for related studies was performed using PubMed, Ichushi-Web, and the Cochrane Library. Data were independently extracted and assessed by two reviewers. A qualitative analysis or meta-analysis was conducted to evaluate six outcomes. Results: Through the first and second screenings, 23 and 18 articles were extracted for qualitative synthesis and meta-analysis, respectively. The incidence of FN was significantly lower in the PEG G-CSF group than in the non-PEG G-CSF group with a strong quality/certainty of evidence. The differences in other outcomes, such as overall survival, infection-related mortality, the duration of neutropenia (less than 500/μL), quality of life, and pain, were not apparent. Conclusions: A single dose of PEG G-CSF is strongly recommended over multiple-dose non-PEG G-CSF therapy for the primary prophylaxis of FN.

    DOI： 10.1007/s10147-024-02504-4

    Web of Science

    Scopus

    PubMed

  • Therapeutic use of granulocyte colony-stimulating factor(G-CSF) in patients with febrile neutropenia: a comprehensive systematic review for clinical practice guidelines for the use of G-CSF 2022 from the Japan Society of Clinical Oncology(タイトル和訳中)

    Tsuchihashi Kenji, Ito Mamoru, Okumura Yuta, Nio Kenta, Ozaki Yukinori, Nishio Hiroshi, Ichihara Eiki, Miura Yuji, Endo Makoto, Yano Shingo, Maruyama Dai, Yoshinami Tetsuhiro, Susumu Nobuyuki, Takekuma Munetaka, Motohashi Takashi, Ochi Nobuaki, Kubo Toshio, Uchino Keita, Kimura Takahiro, Kamiyama Yutaro, Nakao Shinji, Tamura Shinobu, Nishimoto Hitomi, Kato Yasuhisa, Sato Atsushi, Takano Toshimi, Baba Eishi

    International Journal of Clinical Oncology   29 ( 6 )   700 - 705   2024.6   （ ISSN:1341-9625 ）

    　More details

    Language：English   Publisher：シュプリンガー・ジャパン(株)  

  • Therapeutic use of granulocyte colony-stimulating factor (G-CSF) in patients with febrile neutropenia: a comprehensive systematic review for clinical practice guidelines for the use of G-CSF 2022 from the Japan Society of Clinical Oncology

    Tsuchihashi, K; Ito, M; Okumura, Y; Nio, K; Ozaki, Y; Nishio, H; Ichihara, E; Miura, Y; Endo, M; Yano, S; Maruyama, D; Yoshinami, T; Susumu, N; Takekuma, M; Motohashi, T; Ochi, N; Kubo, T; Uchino, K; Kimura, T; Kamiyama, Y; Nakao, S; Tamura, S; Nishimoto, H; Kato, Y; Sato, A; Takano, T; Baba, E

    INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY   29 ( 6 )   700 - 705   2024.6   （ ISSN:1341-9625 eISSN:1437-7772 ）

    　More details

    Language：English   Publisher：International Journal of Clinical Oncology  

    Background: Febrile neutropenia represents a critical oncologic emergency, and its management is pivotal in cancer therapy. In several guidelines, the use of granulocyte colony-stimulating factor (G-CSF) in patients with chemotherapy-induced febrile neutropenia is not routinely recommended except in high-risk cases. The Japan Society of Clinical Oncology has updated its clinical practice guidelines for the use of G-CSF, incorporating a systematic review to address this clinical question. Methods: The systematic review was conducted by performing a comprehensive literature search across PubMed, the Cochrane Library, and Ichushi-Web, focusing on publications from January 1990 to December 2019. Selected studies included randomized controlled trials (RCTs), non-RCTs, and cohort and case–control studies. Evaluated outcomes included overall survival, infection-related mortality, hospitalization duration, quality of life, and pain. Results: The initial search yielded 332 records. Following two rounds of screening, two records were selected for both qualitative and quantitative synthesis including meta-analysis. Regarding infection-related mortality, the event to case ratio was 5:134 (3.73%) in the G-CSF group versus 6:129 (4.65%) in the non-G-CSF group, resulting in a relative risk of 0.83 (95% confidence interval, 0.27–2.58; p = 0.54), which was not statistically significant. Only median values for hospitalization duration were available from the two RCTs, precluding a meta-analysis. For overall survival, quality of life, and pain, no suitable studies were found for analysis, rendering their assessment unfeasible. Conclusion: A weak recommendation is made that G-CSF treatment not be administered to patients with febrile neutropenia during cancer chemotherapy. G-CSF treatment can be considered for patients at high risk.

    DOI： 10.1007/s10147-024-02541-z

    Web of Science

    Scopus

    PubMed

  • Effectiveness of G-CSF in chemotherapy for digestive system tumors: a systematic review of the Clinical Practice Guidelines for the Use of G-CSF 2022 delineated by the Japan Society of Clinical Oncology(タイトル和訳中)

    Ito Mamoru, Okumura Yuta, Nio Kenta, Baba Eishi, Ozaki Yukinori, Nishio Hiroshi, Ichihara Eiki, Miura Yuji, Endo Makoto, Yano Shingo, Maruyama Dai, Yoshinami Tetsuhiro, Susumu Nobuyuki, Takekuma Munetaka, Motohashi Takashi, Ochi Nobuaki, Kubo Toshio, Uchino Keita, Kimura Takahiro, Kamiyama Yutaro, Nakao Shinji, Tamura Shinobu, Nishimoto Hitomi, Kato Yasuhisa, Sato Atsushi, Takano Toshimi, Tsuchihashi Kenji

    International Journal of Clinical Oncology   29 ( 6 )   689 - 699   2024.6   （ ISSN:1341-9625 ）

    　More details

    Language：English   Publisher：シュプリンガー・ジャパン(株)  

  • Effectiveness of G-CSF in chemotherapy for digestive system tumors: a systematic review of the Clinical Practice Guidelines for the Use of G-CSF 2022 delineated by the Japan Society of Clinical Oncology

    Ito, M; Okumura, Y; Nio, K; Baba, E; Ozaki, Y; Nishio, H; Ichihara, E; Miura, Y; Endo, M; Yano, S; Maruyama, D; Yoshinami, T; Susumu, N; Takekuma, M; Motohashi, T; Ochi, N; Kubo, T; Uchino, K; Kimura, T; Kamiyama, Y; Nakao, S; Tamura, S; Nishimoto, H; Kato, Y; Sato, A; Takano, T; Tsuchihashi, K

    INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY   29 ( 6 )   689 - 699   2024.6   （ ISSN:1341-9625 eISSN:1437-7772 ）

    　More details

    Language：English   Publisher：International Journal of Clinical Oncology  

    Background: Granulocyte colony-stimulating factor (G-CSF) reportedly reduces the risk of neutropenia and subsequent infections caused by cancer chemotherapy. Although several guidelines recommend using G-CSF in primary prophylaxis according to the incidence rate of chemotherapy-induced febrile neutropenia (FN), the effectiveness of G-CSF in digestive system tumor chemotherapy remains unclear. To address these clinical questions, we conducted a systematic review as part of revising the Clinical Practice Guidelines for the Use of G-CSF 2022 published by the Japan Society of Clinical Oncology. Methods: This systematic review addressed two main clinical questions (CQ): CQ1: “Is primary prophylaxis with G-CSF effective in chemotherapy?”, and CQ2: “Is increasing the intensity of chemotherapy with G-CSF effective?” We reviewed different types of digestive system tumors, including esophageal, gastric, pancreatic, biliary tract, colorectal, and neuroendocrine carcinomas. PubMed, Cochrane Library, and Ichushi-Web databases were searched for information sources. Independent systematic reviewers conducted two rounds of screening and selected relevant records for each CQ. Finally, the working group members synthesized the strength of evidence and recommendations. Results: After two rounds of screening, 5/0/3/0/2/0 records were extracted for CQ1 of esophageal/gastric/pancreatic/biliary tract/colorectal/ and neuroendocrine carcinoma, respectively. Additionally, a total of 2/6/1 records were extracted for CQ2 of esophageal/pancreatic/colorectal cancer, respectively. The strength of evidence and recommendations were evaluated for CQ1 of colorectal cancer; however, we could not synthesize recommendations for other CQs owing to the lack of records. Conclusion: The use of G-CSF for primary prophylaxis in chemotherapy for colorectal cancer is inappropriate.

    DOI： 10.1007/s10147-024-02502-6

    Web of Science

    Scopus

    PubMed

  • Comparison between a single dose of PEG G-CSF and multiple doses of non-PEG G-CSF: a systematic review and meta-analysis from Clinical Practice Guidelines for the use of G-CSF 2022(タイトル和訳中)

    Yoshinami Tetsuhiro, Nozawa Kazuki, Yokoe Takamichi, Ozaki Yukinori, Nishio Hiroshi, Tsuchihashi Kenji, Ichihara Eiki, Miura Yuji, Endo Makoto, Yano Shingo, Maruyama Dai, Susumu Nobuyuki, Takekuma Munetaka, Motohashi Takashi, Ito Mamoru, Baba Eishi, Ochi Nobuaki, Kubo Toshio, Uchino Keita, Kimura Takahiro, Kamiyama Yutaro, Nakao Shinji, Tamura Shinobu, Nishimoto Hitomi, Kato Yasuhisa, Sato Atsushi, Takano Toshimi

    International Journal of Clinical Oncology   29 ( 6 )   681 - 688   2024.6   （ ISSN:1341-9625 ）

    　More details

    Language：English   Publisher：シュプリンガー・ジャパン(株)  

  • Effectiveness and safety of granulocyte colony-stimulating factor priming regimen for acute myeloid leukemia: A systematic review and meta-analysis of the Clinical Practice Guideline for the use of G-CSF 2022 from the Japan Society of Clinical Oncology

    Najima, Y; Maeda, T; Kamiyama, Y; Nakao, S; Ozaki, Y; Nishio, H; Tsuchihashi, K; Ichihara, E; Miumra, Y; Endo, M; Maruyama, D; Yoshinami, T; Susumu, N; Takekuma, M; Motohashi, T; Ito, M; Baba, E; Ochi, N; Kubo, T; Uchino, K; Kimura, T; Tamura, S; Nishimoto, H; Kato, Y; Sato, A; Takano, T; Yano, S

    INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY   29 ( 7 )   899 - 910   2024.5   （ ISSN:1341-9625 eISSN:1437-7772 ）

    　More details

    Language：English   Publisher：International Journal of Clinical Oncology  

    Background: The outcomes of relapsed or refractory acute myeloid leukemia (AML) remain poor. Although the concomitant use of granulocyte colony-stimulating factor (G-CSF) and anti-chemotherapeutic agents has been investigated to improve the antileukemic effect on AML, its usefulness remains controversial. This study aimed to investigate the effects of G-CSF priming as a remission induction therapy or salvage chemotherapy. Methods: We performed a thorough literature search for studies related to the priming effect of G-CSF using PubMed, Ichushi-Web, and the Cochrane Library. A qualitative analysis of the pooled data was performed, and risk ratios (RRs) with confidence intervals (CIs) were calculated and summarized. Results: Two reviewers independently extracted and accessed the 278 records identified during the initial screening, and 62 full-text articles were assessed for eligibility in second screening. Eleven studies were included in the qualitative analysis and 10 in the meta-analysis. A systematic review revealed that priming with G-CSF did not correlate with an improvement in response rate and overall survival (OS). The result of the meta-analysis revealed the tendency for lower relapse rate in the G-CSF priming groups without inter-study heterogeneity [RR, 0.91 (95% CI 0.82–1.01), p = 0.08; I2 = 4%, p = 0.35]. In specific populations, including patients with intermediate cytogenetic risk and those receiving high-dose cytarabine, the G-CSF priming regimen prolonged OS. Conclusions: G-CSF priming in combination with intensive remission induction treatment is not universally effective in patients with AML. Further studies are required to identify the patient cohort for which G-CSF priming is recommended.

    DOI： 10.1007/s10147-023-02461-4

    Web of Science

    Scopus

    PubMed

  • 前立腺癌に対する化学療法におけるG-CSFの一次予防の有効性と安全性、G-CSFの適正使用に関する日本の臨床ガイドライン　G-CSF適正使用ガイドライン2022年版(Effectiveness and safety of primary prophylaxis of G-CSF during chemotherapy for prostate cancer, Japanese clinical guideline for appropriate use of G-CSF: clinical practice guidelines for the use of G-CSF 2022)

    Kimura Shoji, Shigeta Keisuke, Tamura Shingo, Uchino Keita, Kimura Takahiro, Ozaki Yukinori, Nishio Hiroshi, Tsuchihashi Kenji, Ichihara Eiki, Endo Makoto, Yano Shingo, Maruyama Dai, Yoshinami Tetsuhiro, Susumu Nobuyuki, Takekuma Munetaka, Motohashi Takashi, Ito Mamoru, Baba Eishi, Ochi Nobuaki, Kubo Toshio, Kamiyama Yutaro, Nakao Shinji, Tamura Shinobu, Nishimoto Hitomi, Kato Yasuhisa, Sato Atsushi, Takano Toshimi, Miura Yuji

    International Journal of Clinical Oncology   29 ( 5 )   559 - 563   2024.5   （ ISSN:1341-9625 ）

    　More details

    Language：English   Publisher：シュプリンガー・ジャパン(株)  

    前立腺癌に対するカバジタキセル(CBZ)投与中における顆粒球コロニー刺激因子(G-CSF)の一次予防的投与が臨床転帰に及ぼす影響について検討するため、Mindsのガイドラインに従ってシステマティックレビューを行った。PubMed、Cochrane Library、医中誌Webにおいて1990年1月～2019年12月31日に発表された研究を検索し、最終的に9件の論文が定性的システマティックレビューに含まれた。転移性去勢抵抗性前立腺癌に対するCBZ投与中のG-CSF一次予防は、全生存期間、感染による死亡率、および患者のQOLとの相関の点で評価が困難であった。そのような困難さは、CBZ投与中にG-CSFの一次予防を行った患者と行わなかった患者を比較した無作為化比較試験が存在しないことに起因すると考えられた。しかし、いくつかの後ろ向き研究では、G-CSFが発熱性好中球減少症の発生率を低下させる可能性が示唆された。以上より、G-CSFは転移性去勢抵抗性前立腺癌に対するCBZ投与中の一次予防として有益である可能性があり、関連するレジメンの注釈とともに「行うべき弱い推奨」とした。

  • 癌患者に対する化学療法後の予防的ペグ化G-CSFの最適なタイミング　G-CSF適正使用ガイドライン2022年版のシステマティックレビューとメタアナリシス(Optimal timing of prophylactic pegylated G-CSF after chemotherapy administration for patients with cancer: a systematic review and meta-analysis from Clinical Practice Guidelines for the use of G-CSF 2022)

    Ozaki Yukinori, Yokoe Takamichi, Yoshinami Tetsuhiro, Nozawa Kazuki, Nishio Hiroshi, Tsuchihashi Kenji, Ichihara Eiki, Miura Yuji, Endo Makoto, Yano Shingo, Maruyama Dai, Susumu Nobuyuki, Takekuma Munetaka, Motohashi Takashi, Ito Mamoru, Baba Eishi, Ochi Nobuaki, Kubo Toshio, Uchino Keita, Kimura Takahiro, Kamiyama Yutaro, Nakao Shinji, Tamura Shinobu, Nishimoto Hitomi, Kato Yasuhisa, Sato Atsushi, Takano Toshimi

    International Journal of Clinical Oncology   29 ( 5 )   551 - 558   2024.5   （ ISSN:1341-9625 ）

    　More details

    Language：English   Publisher：シュプリンガー・ジャパン(株)  

    化学療法終了後の予防的ペグ化顆粒球コロニー刺激因子(ペグ化G-CSF)の最適な投与タイミングを有効性や有害事象の点から検討するためシステマティックレビューを行った。1990年1月～2019年12月に発表されたPubMed、医中誌Web、Cochrane Libraryを用いて、「診療ガイドライン作成のためのMindsハンドブック2014」と「Minds診療ガイドライン作成マニュアル2017」に従った。2名のレビュアーが独立してデータを抽出し評価した。最初の検索結果300件のうち、組み入れ基準を満たした論文は4件のみであった。発熱性好中球減少症の発生率に関するメタアナリシスでは、ペグ化G-CSFが2日目よりも3～5日目に投与された場合に発生率が高くなる可能性が示唆され(オッズ比1.27、95%CI 0.66～2.46、p=0.47)、エビデンスの確実性は中程度であった。全生存期間および感染症による死亡率に有意差はなかった。重篤な有害事象の発生傾向はペグ化G-CSF投与3～5日目に低かったが、統計的有意差はなく(オッズ比0.72、95%CI 0.14～3.67、p=0.69)、エビデンスの確実性は中程度であった。疼痛に関するデータは結論に至らなかった。以上より、癌患者における化学療法後のペグ化G-CSF投与については、2日目と3～5日目の両方が弱く推奨された。

  • 急性骨髄性白血病に対する導入療法後のG-CSFによる一次予防の有効性と安全性　日本癌治療学会のG-CSF適正使用ガイドライン2022年版のシステマティックレビューとメタアナリシス(Effectiveness and safety of primary prophylaxis with G-CSF after induction therapy for acute myeloid leukemia: a systematic review and meta-analysis of the clinical practice guidelines for the use of G-CSF 2022 from the Japan society of clinical oncology)

    Maeda Tomoya, Najima Yuho, Kamiyama Yutaro, Nakao Shinji, Ozaki Yukinori, Nishio Hiroshi, Tsuchihashi Kenji, Ichihara Eiki, Miumra Yuji, Endo Makoto, Maruyama Dai, Yoshinami Tatsuhiro, Susumu Nobuyuki, Takekuma Munetaka, Motohashi Takashi, Ito Mamoru, Baba Eishi, Ochi Nobuaki, Kubo Toshio, Uchino Keita, Kimura Takahiro, Tamura Shinobu, Nishimoto Hitomi, Kato Yasuhisa, Sato Atsushi, Takano Toshimi, Yano Shingo

    International Journal of Clinical Oncology   29 ( 5 )   535 - 544   2024.5   （ ISSN:1341-9625 ）

    　More details

    Language：English   Publisher：シュプリンガー・ジャパン(株)  

    顆粒球コロニー刺激因子(G-CSF)受容体を発現する急性骨髄性白血病(AML)に対するG-CSFの予防的使用には再発リスクの懸念があり、依然として議論の的となっている。本研究では、AMLに対するG-CSFによる一次的予防投与の効果について検討するため、システマティックレビューを実施した。PubMed、医中誌Web、Cochrane Libraryを用いて、「診療ガイドライン作成のためのMindsハンドブック2014」と「Minds診療ガイドライン作成マニュアル2017」に従った。データを2名のレビュアーが独立して抽出し評価した。プールしたデータの質的分析を行い、対応する信頼区間を伴うリスク比をメタアナリシスで算出し要約した。16件の研究が質的分析に含まれ、そのうち9件をメタアナリシスで検討した。その結果、G-CSFは好中球減少の期間を有意に短縮したが、G-CSFによる一次予防は感染関連死亡率と相関しなかった。さらに、G-CSFによる一次予防は、疾患の進行/再発、全生存、および筋骨格痛などの有害事象には影響しなかった。しかし、寛解導入療法を受けた成人AML患者に対する一次予防としてのG-CSFの使用を支持または妨げるエビデンスはまだ限られていた。以上より、導入療法中の一次予防薬としてのG-CSFの使用は感染性合併症のリスクが高い成人AML患者に対してのみ考慮する必要があることが示された。

  • 尿路上皮癌に対するdose-dense化学療法中の顆粒球コロニー刺激因子による一次予防の有効性と安全性　G-CSF適正使用ガイドライン2022年版(Effectiveness and safety of primary prophylaxis of granulocyte colony-stimulating factor during dose-dense chemotherapy for urothelial cancer: Clinical Practice Guidelines for the Use of G-CSF 2022)

    Uchino Keita, Tamura Shingo, Kimura Shoji, Shigeta Keisuke, Kimura Takahiro, Ozaki Yukinori, Nishio Hiroshi, Tsuchihashi Kenji, Ichihara Eiki, Endo Makoto, Yano Shingo, Maruyama Dai, Yoshinami Tetsuhiro, Susumu Nobuyuki, Takekuma Munetaka, Motohashi Takashi, Ito Mamoru, Baba Eishi, Ochi Nobuaki, Kubo Toshio, Kamiyama Yutaro, Nakao Shinji, Tamura Shinobu, Nishimoto Hitomi, Kato Yasuhisa, Sato Atsushi, Takano Toshimi, Miura Yuji

    International Journal of Clinical Oncology   29 ( 5 )   545 - 550   2024.5   （ ISSN:1341-9625 ）

    　More details

    Language：English   Publisher：シュプリンガー・ジャパン(株)  

    発熱性好中球減少症(FN)の発生率に基づいて顆粒球コロニー刺激因子(G-CSF)の一次的予防投与の妥当性を判断するのではなく、システマティックレビューにより尿路上皮癌に対するG-CSFの一次予防投与の有用性を評価した。PubMed、医中誌Web、Cochrane Libraryを用いて、「診療ガイドライン作成のためのMindsハンドブック2014」と「Minds診療ガイドライン作成マニュアル2017」に従った。データを2名のレビュアーが独立して抽出し評価した。プールされたデータの定性的分析を行い、リスク比とそれに対応する信頼区間を算出し、メタアナリシスにまとめた。質的分析には7件の研究が含まれ、そのうち2件はdose-denseメトトレキサート、ビンブラスチン、ドキソルビシン、シスプラチン(MVAC)療法に関するメタアナリシスでレビューし、1件の無作為化比較研究ではFN発生率の減少が示された。G-CSFの一次的予防投与はdose-dense MVAC療法の無作為化比較試験で示されたように有益である可能性があった。しかし、他のレジメンに関する研究はなかったことから、意義のあるレジメン(dose-dense MVAC)の注釈を付して「行うべき弱い推奨」とした。

  • Effectiveness and safety of primary prophylaxis with G-CSF for lung cancer: a systematic review and meta-analysis to develop clinical practice guidelines for the use of G-CSF 2022

    Ichihara, E; Ochi, N; Makimoto, G; Kudo, K; Harada, D; Ozaki, Y; Nishio, H; Tsuchihashi, K; Miura, Y; Endo, M; Yano, S; Maruyama, D; Yoshinami, T; Susumu, N; Takekuma, M; Motohashi, T; Ito, M; Baba, E; Uchino, K; Kimura, T; Kamiyama, Y; Nakao, S; Tamura, S; Nishimoto, H; Kato, Y; Sato, A; Takano, T; Kubo, T

    INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY   29 ( 4 )   355 - 362   2024.4   （ ISSN:1341-9625 eISSN:1437-7772 ）

    　More details

    Language：English   Publisher：International Journal of Clinical Oncology  

    Background: Granulocyte colony-stimulating factor (G-CSF) is commonly administered to cancer patients undergoing myelosuppressive chemotherapy, especially when incidence rate of febrile neutropenia (FN) surpasses 20%. While primary prophylaxis with G-CSF has been proven effective in preventing FN in patients with cancer, there is limited evidence regarding its efficacy in specifically, lung cancer. Our systematic review focused on the efficacy of G-CSF primary prophylaxis in lung cancer. Methods: We extracted studies on non-small-cell lung cancer (NSCLC) and small-cell lung cancer (SCLC) using the PubMed, Ichushi Web, and Cochrane Library databases. Two reviewers assessed the extracted studies for each type of lung cancer and conducted quantitative and meta-analyses of preplanned outcomes, including overall survival, FN incidence, infection-related mortality, quality of life, and musculoskeletal pain. Results: A limited number of studies were extracted: two on NSCLC and six on SCLC. A meta-analysis was not conducted owing to insufficient data on NSCLC. Two case–control studies explored the efficacy of primary prophylaxis with G-CSF in patients with NSCLC (on docetaxel and ramucirumab therapy) and indicated a lower FN frequency with G-CSF. For SCLC, meta-analysis of five studies showed no significant reduction in FN incidence, with an odds ratio of 0.38 (95% confidence interval 0.03–5.56, P = 0.48). Outcomes other than FN incidence could not be evaluated due to low data availability. Conclusion: Limited data are available on G-CSF prophylaxis in lung cancer. Primary prophylaxis with G-CSF may be weakly recommended in Japanese patients with NSCLC undergoing docetaxel and ramucirumab combination therapy.

    DOI： 10.1007/s10147-024-02469-4

    Web of Science

    Scopus

    PubMed

  • 肺癌に対するG-CSFによる一次予防の有効性と安全性　G-CSF適正使用ガイドライン(2022年版)を作成するためのシステマティックレビューとメタアナリシス(Effectiveness and safety of primary prophylaxis with G-CSF for lung cancer: a systematic review and meta-analysis to develop clinical practice guidelines for the use of G-CSF 2022)

    Ichihara Eiki, Ochi Nobuaki, Makimoto Go, Kudo Kenichiro, Harada Daijiro, Ozaki Yukinori, Nishio Hiroshi, Tsuchihashi Kenji, Miura Yuji, Endo Makoto, Yano Shingo, Maruyama Dai, Yoshinami Tetsuhiro, Susumu Nobuyuki, Takekuma Munetaka, Motohashi Takashi, Ito Mamoru, Baba Eishi, Uchino Keita, Kimura Takahiro, Kamiyama Yutaro, Nakao Shinji, Tamura Shinobu, Nishimoto Hitomi, Kato Yasuhisa, Sato Atsushi, Takano Toshimi, Kubo Toshio

    International Journal of Clinical Oncology   29 ( 4 )   355 - 362   2024.4   （ ISSN:1341-9625 ）

    　More details

    Language：English   Publisher：シュプリンガー・ジャパン(株)  

    日本癌治療学会による「G-CSF適正使用ガイドライン(2022年版)」の作成に役立てるため、肺癌患者に対し顆粒球コロニー刺激因子(G-CSF)を用いて発熱性好中球減少症(FN)を一次予防する手法の有効性に着目したシステマティックレビューとメタアナリシスを施行した。各種文献データベースを用いて2020年3月27日に関連文献を検索し、最終的に非小細胞肺癌(NSCLC)に関する研究2報と小細胞肺癌(SCLC)の研究6報を選出した。NSCLCに関してはデータが不十分であったためメタアナリシスは行わなかった。NSCLCの2報はいずれも症例対照研究であり、ドセタキセルとラムシルマブでの併用治療を受けている患者に対し、G-CSF一次予防法によってFN発症頻度が低下したことが示されていた。次にSCLC研究の5報を組み入れ、メタアナリシスを施行したが、FN発症率の有意な低下は示されなかった。あらかじめ設定していた評価項目のうち、FN発症率以外のものについては、データの利用可能性が低かったために評価不能であった。

  • Effectiveness and safety of primary prophylaxis of granulocyte colony-stimulating factor during dose-dense chemotherapy for urothelial cancer: Clinical Practice Guidelines for the Use of G-CSF 2022 Invited Reviewed International journal

    Keita Uchino, Shingo Tamura, Shoji Kimura, Keisuke Shigeta, Takahiro Kimura, Yukinori Ozaki, Hiroshi Nishio, Kenji Tsuchihashi, Eiki Ichihara, Makoto Endo, Shingo Yano, Dai Maruyama, Tetsuhiro Yoshinami, Nobuyuki Susumu, Munetaka Takekuma, Takashi Motohashi, Mamoru Ito, Eishi Baba, Nobuaki Ochi, Toshio Kubo, Yutaro Kamiyama, Shinji Nakao, Shinobu Tamura, Hitomi Nishimoto, Yasuhisa Kato , Atsushi Sato, Toshimi Takano, Yuji Miura

    Int J Clin Oncol   2024.3

    　More details

    Language：Japanese   Publishing type：Research paper (scientific journal)  

  • Optimal timing of prophylactic pegylated G-CSF after chemotherapy administration for patients with cancer: a systematic review and meta-analysis from Clinical Practice Guidelines for the use of G-CSF 2022 Invited Reviewed International journal

    Yukinori Ozaki, Takamichi Yokoe, Tetsuhiro Yoshinami, Kazuki Nozawa, Hiroshi Nishio, Kenji Tsuchihashi, Eiki Ichihara, Yuji Miura, Makoto Endo, Shingo Yano, Dai Maruyama, Nobuyuki Susumu, Munetaka Takekuma, Takashi Motohashi, Mamoru Ito, Eishi Baba, Nobuaki Ochi, Toshio Kubo, Keita Uchino, Takahiro Kimura, Yutaro Kamiyama, Shinji Nakao, Shinobu Tamura, Hitomi Nishimoto, Yasuhisa Kato, Atsushi Sato, Toshimi Takano

    Int J Clin Oncol   2024.3

    　More details

    Language：Japanese   Publishing type：Research paper (scientific journal)  

  • Effectiveness and safety of primary prophylaxis of G-CSF during chemotherapy for prostate cancer, Japanese clinical guideline for appropriate use of G-CSF: clinical practice guidelines for the use of G-CSF 2022 Invited Reviewed International journal

    Shoji Kimura, Keisuke Shigeta, Shingo Tamura, Keita Uchino, Takahiro Kimura, Yukinori Ozaki, Hiroshi Nishio, Kenji Tsuchihashi, Eiki Ichihara, Makoto Endo, Shingo Yano, Dai Maruyama, Tetsuhiro Yoshinami, Nobuyuki Susumu, Munetaka Takekuma, Takashi Motohashi, Mamoru Ito, Eishi Baba, Nobuaki Ochi, Toshio Kubo, Yutaro Kamiyama, Shinji Nakao, Shinobu Tamura, Hitomi Nishimoto, Yasuhisa Kato , Atsushi Sato, Toshimi Takano, Yuji Miura

    Int J Clin Oncol   2024.3

    　More details

    Language：Japanese   Publishing type：Research paper (scientific journal)  

  • Effectiveness and safety of primary prophylaxis with G-CSF after induction therapy for acute myeloid leukemia: a systematic review and meta-analysis of the clinical practice guidelines for the use of G-CSF 2022 from the Japan society of clinical oncology Invited Reviewed International journal

    Tomoya Maeda, Yuho Najima, Yutaro Kamiyama, Shinji Nakao, Yukinori Ozaki, Hiroshi Nishio, Kenji Tsuchihashi, Eiki Ichihara, Yuji Miumra , Makoto Endo, Dai Maruyama, Tatsuhiro Yoshinami, Nobuyuki Susumu, Munetaka Takekuma, Takashi Motohashi, Mamoru Ito, Eishi Baba , Nobuaki Ochi, Toshio Kubo, Keita Uchino, Takahiro Kimura, Shinobu Tamura, Hitomi Nishimoto, Yasuhisa Kato, Atsushi Sato, Toshimi Takano, Shingo Yano

    Int J Clin Oncol   2024.3

    　More details

    Language：Japanese   Publishing type：Research paper (scientific journal)  

  • Impact of Genomic Alterations on Efficacy of Trastuzumab Deruxtecan Against Human Epidermal Growth Factor Receptor-2-Positive Advanced Gastric Cancer

    Yamaguchi, K; Ito, M; Isobe, T; Koreishi, S; Taguchi, R; Uehara, K; Ueno, S; Imajima, T; Kitazono, T; Tsuchihashi, K; Ohmura, H; Yoshihiro, T; Tanoue, K; Nishiyori, S; Iwama, E; Maeda, T; Akashi, K; Baba, E

    JCO PRECISION ONCOLOGY   8   e2300681   2024.3   （ eISSN:2473-4284 ）

    　More details

    Language：English   Publisher：JCO Precision Oncology  

    PURPOSE The impact of genomic alterations on response and resistance to trastuzumab deruxtecan (T-DXd) has not been elucidated. Thus, we sought to identify factors predicting sensitivity to T-DXd in gastric or gastroesophageal junction (G/GEJ) cancer. METHODS We conducted a retrospective study using real-world clinical data and next-generation sequencing–based comprehensive genomic profiling (CGP) data from patients with advanced G/GEJ cancers, collected by the nationwide database in Japan. We analyzed the associations between genomic alterations and the patients’ survivals after T-DXd treatment. RESULTS In 114 patients with human epidermal growth factor receptor-2 (HER2)–positive G/GEJ cancer treated with T-DXd, the most frequently altered genes were TP53 (82%), ERBB2 (80%), and CCNE1 (36%). Multivariate Cox regression analysis revealed CCNE1 amplification to be a significant predictor of shorter progression-free survival (PFS) after T-DXd treatment among 91 patients whose CGP samples were obtained before T-DXd (median PFS, 131 days v 189 days; hazard ratio [HR], 1.90 [95% CI, 1.02 to 3.53]; P 5 .044). Analyses of 1,450 G/GEJ cancers revealed significant CCNE1/ERBB2 coamplification (41% relative to 11% CCNE1 amplification in ERBB2-nonamplified tumors; P < .0001). ERBB2-activating mutations were also detected in 3.7% of G/GEJ cancers and in 8.8% of HER2-positive G/GEJ cancers treated with T-DXd. Patients with ERBB2-mutated tumors showed shorter PFS than those without ERBB2 mutations after T-DXd treatment (mPFS, 105 v 180 days; P 5 .046). CONCLUSION CCNE1 amplification may confer primary resistance to T-DXd in HER2-positive G/GEJ cancer, suggesting that the cell cycle could be a potential therapeutic target in CCNE1/ERBB2 coamplified tumors. ERBB2-activating mutation may also attenuate T-DXd efficacy in HER2-positive G/GEJ cancer.

    DOI： 10.1200/PO.23.00681

    Web of Science

    Scopus

    PubMed

  • Lymphoproliferative Disorder in an Esophageal Cancer Patient Treated with Pembrolizumab

    Matsumura Takashi, Tsuchihashi Kenji, Yamamoto Takeo, Jinnouchi Fumiaki, Kusano Wataru, Kusumoto Yota, Arimizu Kohei, Ohmura Hirofumi, Kuma Yuki, Moriyama Shohei, Yamaguchi Kyoko, Ito Mamoru, Isobe Taichi, Ariyama Hiroshi, Oda Yoshinao, Akashi Koichi, Baba Eishi

    Internal Medicine   advpub ( 0 )   2024   （ ISSN:09182918 eISSN:13497235 ）

    　More details

    Language：English   Publisher：The Japanese Society of Internal Medicine  

    <p>A 75-year-old man diagnosed with esophageal cancer and lung metastasis received a combination of fluorouracil, cisplatin, and pembrolizumab. During pembrolizumab maintenance therapy, lymphoproliferative lesions at the lips and mouth and multiple lymph node swellings appeared. Histologically, Epstein-Barr virus (EBV)-encoded RNA was positive, and EBV-DNA was detected in the blood. The patient was diagnosed with other iatrogenic immunodeficiency-associated lymph proliferative disorders (OIIA-LPDs) related to EBV activation induced by pembrolizumab. Rituximab was administered, resulting in the improvement of the OIIA-LPD. The emergence of an OIIA-LPD merits close attention in patients receiving immune checkpoint inhibitors. </p>

    DOI： 10.2169/internalmedicine.3743-24

    Web of Science

    PubMed

    CiNii Research

  • Preferential B cell differentiation by combined immune checkpoint blockade for renal cell carcinoma is associated with clinical response and autoimmune reactions Reviewed International journal

    Koki Uehara, Kenro Tanoue, Kyoko Yamaguchi, Hirofumi Ohmura, Mamoru Ito, Yuzo Matsushita, Kenji Tsuchihashi, Shingo Tamura, Hozumi Shimokawa, Taichi Isobe, Yoshihiro Shibata, Hiroshi Ariyama, Risa Tanaka, Hitoshi Kusaba, Hidetaka Yamamoto, Yoshinao Oda, Koichi Akashi, Eishi Baba

    Cancer Immunol Immunother   2023.11

    　More details

    Language：Japanese   Publishing type：Research paper (scientific journal)  

  • Chemotherapy for advanced urachal carcinoma: A case series of three patients

    Kitazono, T; Ito, M; Tsuchihashi, K; Isobe, T; Matsumura, T; Takigawa, A; Arimizu, K; Ariyama, H; Baba, E

    ANNALS OF ONCOLOGY   34   S1448 - S1448   2023.11   （ ISSN:0923-7534 eISSN:1569-8041 ）

    　More details

  • Outcome of parameningeal head and neck rhabdomyosarcoma in adults: Kyushu Medical Oncology Group Study

    Isobe, T; Tsuchihashi, K; Ueno, S; Taguchi, R; Ito, M; Nakano, M; Ariyama, H; Hanamura, F; Okumura, Y; Komoda, M; Esaki, T; Arita, S; Nio, K; Kusaba, H; Hashimoto, K; Yoshitake, T; Oda, Y; Akashi, K; Baba, E

    ANNALS OF ONCOLOGY   34   S1409 - S1409   2023.11   （ ISSN:0923-7534 eISSN:1569-8041 ）

    　More details

  • Multicenter retrospective study of vulnerable patients with metastatic colorectal cancer: Results of second-line therapy

    Kawakami, K; Kito, Y; Mitani, S; Hino, K; Izawa, N; Hanamura, F; Yamamoto, Y; Shoji, H; Komori, A; Boku, S; Tsuchihashi, K; Baba, E; Kato, K; Nonagase, Y; Matsumoto, T; Furuta, M; Kawakami, H

    ANNALS OF ONCOLOGY   34   S1406 - S1407   2023.11   （ ISSN:0923-7534 eISSN:1569-8041 ）

    　More details

  • Efficacy and safety of chemotherapy in metastatic malignant phyllodes tumors

    Takigawa, A; Nio, K; Arimizu, K; Ito, M; Tsuchihashi, K; Isobe, D; Ariyama, H; Ide, K; Matsushita, Y; Tanaka, R; Koichi, A; Baba, E

    ANNALS OF ONCOLOGY   34   S1410 - S1411   2023.11   （ ISSN:0923-7534 eISSN:1569-8041 ）

    　More details

  • Case Report: Resolution of remitting seronegative symmetrical synovitis with pitting edema during nivolumab therapy for gastric cancer Reviewed International journal

    Hirofumi Ohmura, Moe Kondo, Masato Uenomachi, Hiroshi Ariyama, Mamoru Ito, Kenji Tsuchihashi, Masahiro Ayano, Hiroaki Niiro, Koichi Akashi, Eishi Baba

    Front Oncol   2023.10

    　More details

    Language：Japanese   Publishing type：Research paper (scientific journal)  

  • Real-World Treatment Sequencing in Vulnerable Patients with Metastatic Colorectal Cancer: A Multicenter Retrospective Study Reviewed International journal

    Seiichiro Mitani, Yosuke Kito, Kaori Hino, Kentaro Kawakami, Naoki Izawa, Fumiyasu Hanamura, Yoshiyuki Yamamoto, Hirokazu Shoji, Azusa Komori, Shogen Boku, Kenji Tsuchihashi, Kyoko Kato, Yoshikane Nonagase, Toshihiko Matsumoto, Mitsuhiro Furuta, Hisato Kawakami

    Target Oncol   2023.9

    　More details

    Language：Japanese   Publishing type：Research paper (scientific journal)  

  • Vulnerable patients with metastatic colorectal cancer in a real-world setting: A multicenter retrospective study.

    Mitani, S; Kito, Y; Hino, K; Kawakami, K; Izawa, N; Hanamura, F; Yamamoto, Y; Shoji, H; Komori, A; Boku, S; Tsuchihashi, K; Baba, E; Kato, K; Nonagase, Y; Matsumoto, T; Furuta, M; Kawakami, H

    JOURNAL OF CLINICAL ONCOLOGY   41   114 - 114   2023.2   （ ISSN:0732-183X eISSN:1527-7755 ）

    　More details

  • Circulating <i>stem-like</i> PD-1+CD8 T cells responding to PD-1 blockade predict clinical outcomes in esophageal cancer

    Tanoue, K; Ohmura, H; Yamaguchi, K; Tsuchihashi, K; Tamura, S; Isobe, T; Ariyama, H; Esaki, T; Akashi, K; Baba, E

    CANCER SCIENCE   114   821 - 821   2023.2   （ ISSN:1347-9032 eISSN:1349-7006 ）

    　More details

  • The amplification of TPX2 is a potential biomarker of oxaliplatin-susceptibility in colorectal cancer

    Ueno, S; Isobe, T; Taguchi, R; Tsuchihashi, K; Ariyama, H; Akashi, K; Baba, E

    CANCER SCIENCE   114   1449 - 1449   2023.2   （ ISSN:1347-9032 eISSN:1349-7006 ）

    　More details

  • DNMT3B maintains the organoid-formation ability of left-sided colorectal cancer derived from patients

    Taguchi, R; Isobe, T; Ueno, S; Kikushige, Y; Tsuchihashi, K; Ariyama, H; Akashi, K; Baba, E

    CANCER SCIENCE   114   1220 - 1220   2023.2   （ ISSN:1347-9032 eISSN:1349-7006 ）

    　More details

  • Circulating <i>stem</i>-<i>like</i> PD-1+CD8 T cells responding to PD-1 blockade predict clinical outcomes in esophageal cancer

    Tanoue, K; Ohmura, H; Yamaguchi, K; Tsuchihashi, K; Tamura, S; Isobe, T; Ariyama, H; Esaki, T; Akashi, K; Baba, E

    CANCER SCIENCE   114   1179 - 1179   2023.2   （ ISSN:1347-9032 eISSN:1349-7006 ）

    　More details

  • Inhibition of insulin-like growth factor-1 receptor enhances eribulin-induced DNA damage in colorectal cancer Reviewed International journal

    Yoshihiro T, Ariyama H, Yamaguchi K, Imajima T, Yamaga S, Tsuchihashi K, Isobe T, Kusaba H, Akashi K, Baba E.

    Cancer Sci   113   4207 - 4218   2022.12

    　More details

    Language：Japanese   Publishing type：Research paper (scientific journal)  

  • インスリン様成長因子-1受容体の阻害は大腸癌におけるエリブリン誘発DNA損傷を増強する(Inhibition of insulin-like growth factor-1 receptor enhances eribulin-induced DNA damage in colorectal cancer)

    Yoshihiro Tomoyasu, Ariyama Hiroshi, Yamaguchi Kyoko, Imajima Takashi, Yamaga Satoru, Tsuchihashi Kenji, Isobe Taichi, Kusaba Hitoshi, Akashi Koichi, Baba Eishi

    Cancer Science   113 ( 12 )   4207 - 4218   2022.12   （ ISSN:1347-9032 ）

    　More details

    Language：English   Publisher：John Wiley & Sons Australia, Ltd  

    クロイソカイメンから発見されたハリコンドリンBの誘導体である微小管標的薬エリブリン(Eri)に対する耐性のメカニズムについて検討した。Eri耐性大腸癌由来SW480細胞におけるインスリン様成長因子-1受容体(IGF-1R)/インスリン受容体(INSR)活性化に対するEri処理の影響を分析した。その結果、Eriへの曝露により、リン酸化されたIGF-1R/INSRとその下流エフェクターにおけるAktの蓄積量が増加し、IGFシグナルが活性化された。Eri処理はIGF-1Rの活性化とそれに続く核移行を誘導したが、IGF-1Rの活性化や核移行を阻害した場合、EriはDNA損傷を誘導し、G2/M停止を促進した。さらに、Eri耐性細胞株であるSW480を用いた異種移植マウスモデルにおいて、EriとIGF-1R阻害剤であるリンシチニブの併用は、いずれの単剤よりも腫瘍増殖を抑制した。以上より、EriとIGF-1R阻害剤の併用はEri耐性を克服することが示唆された。

  • Late line FOLFOX therapy after prior cisplatin-based regimen in advanced esophageal squamous cell carcinoma: A multi-institutional retrospective study

    Shimozaki, K; Sugiyama, K; Koya, S; Shiraishi, K; Okada, M; Matsubara, Y; Furuta, M; Hirose, S; Komori, A; Mitani, S; Boku, S; Nishimura, T; Tsuchihashi, K; Kito, Y; Sugaya, A; Masuishi, T; Matsumoto, T; Tsuzuki, T; Yoshii, T; Hirata, K

    ANNALS OF ONCOLOGY   33   S1481 - S1481   2022.11   （ ISSN:0923-7534 eISSN:1569-8041 ）

    　More details

  • Sheath-wedged Aspiration Biopsy for the Diagnosis of a Cardiac Mass Reviewed International journal

    Moriyama S, Yokoyama T, Tsuchihashi K, Fukata M.

    Intern Med   61   2987 - 2988   2022.10

    　More details

    Language：Japanese   Publishing type：Research paper (scientific journal)  

  • IMPROVE bleeding score predicts major bleeding in advanced gastrointestinal cancer patients with venous thromboembolism Reviewed International journal

    Kusaba H, Moriyama S, Hieda M, Ito M, Ohmura H, Isobe T, Tsuchihashi K, Fukata M, Ariyama H, Baba E.

    Jpn J Clin Oncol   10   1183 - 1190   2022.10

    　More details

    Language：Japanese   Publishing type：Research paper (scientific journal)  

  • IMPROVE出血スコアは静脈血栓塞栓症を有する進行消化器癌患者における大出血を予測する(IMPROVE bleeding score predicts major bleeding in advanced gastrointestinal cancer patients with venous thromboembolism)

    Kusaba Hitoshi, Moriyama Shohei, Hieda Michinari, Ito Mamoru, Ohmura Hirofumi, Isobe Taichi, Tsuchihashi Kenji, Fukata Mitsuhiro, Ariyama Hiroshi, Baba Eishi

    Japanese Journal of Clinical Oncology   52 ( 10 )   1183 - 1190   2022.10   （ ISSN:0368-2811 ）

    　More details

    Language：English   Publisher：Oxford University Press  

    癌関連血栓症を有する進行消化器癌患者に対する抗凝固療法の患者選択を改善するため、出血の発生率や危険因子を後方視的に検討した。2014～2018年に化学療法を受けた進行消化器癌患者194例(年齢31～84歳)を対象とした。消化器癌の内訳は胃癌74例、大腸癌120例であった。194例のうち、静脈血栓塞栓症と診断された患者は40例(20.6%)、肺血栓塞栓症を併発した患者は10例(5.2%)であった。出血は29名(15%)に認められた。出血部位は、原発巣17例、転移巣9例、出血性胃潰瘍3例であり、静脈血栓塞栓症群40例のうち10例(25%)に出血が認められた。多変量解析により、International Medical Prevention Registry on Venous Thromboembolism(IMPROVE)出血スコア7以上と大出血は有意に相関していた(P=0.01)。出血リスクの低い患者では大出血は3例のみであった。以上より、IMPROVE出血スコアは静脈血栓塞栓症を有する消化器癌患者における出血リスクを予測する可能性があった。

  • Potential therapeutic targets discovery by transcriptome analysis of an in vitro human gastric signet ring carcinoma model Reviewed International journal

    Yamaguchi K, Yoshihiro T, Ariyama H, Ito M, Nakano M, Semba Y, Nogami J, Tsuchihashi K, Yamauchi T, Ueno S, Isobe T, Shindo K, Moriyama T, Ohuchida K, Nakamura M, Nagao Y, Ikeda T, Hashizume M, Konomi H, Torisu T, Kitazono T, Kanayama T, Tomita H, Oda Y, Kusaba H, Maeda T, Akashi K, Baba E.

    Gastric Cancer   25   862 - 878   2022.9

    　More details

    Language：Japanese   Publishing type：Research paper (scientific journal)  

  • in vitroヒト胃印環細胞癌モデルのトランスクリプトーム解析による潜在的な治療標的の発見(Potential therapeutic targets discovery by transcriptome analysis of an in vitro human gastric signet ring carcinoma model)

    Yamaguchi Kyoko, Yoshihiro Tomoyasu, Ariyama Hiroshi, Ito Mamoru, Nakano Michitaka, Semba Yuichiro, Nogami Jumpei, Tsuchihashi Kenji, Yamauchi Takuji, Ueno Shohei, Isobe Taichi, Shindo Koji, Moriyama Taiki, Ohuchida Kenoki, Nakamura Masafumi, Nagao Yoshihiro, Ikeda Tetsuo, Hashizume Makoto, Konomi Hiroyuki, Torisu Takehiro, Kitazono Takanari, Kanayama Tomohiro, Tomita Hiroyuki, Oda Yoshinao, Kusaba Hitoshi, Maeda Takahiro, Akashi Koichi, Baba Eishi

    Gastric Cancer   25 ( 5 )   862 - 878   2022.9   （ ISSN:1436-3291 ）

    　More details

    Language：English   Publisher：シュプリンガー・ジャパン(株)  

    E-カドヘリン欠損胃印環細胞癌(SRCC)における新規治療標的を同定することを目的とした。E-カドヘリンをコードするCDH1遺伝子をノックアウト(KO)したヒト胃オルガノイド(hGO)を用いて、in vitroのE-カドヘリン欠損胃癌モデルを作製し、新規治療標的を探索した。CDH1 KO hGO細胞は、SRCCに類似した特徴的な形態変化と高い細胞運動性を示した。RNA配列解析の結果、CDH1 KO hGO細胞では、野生型と比較して、マトリックスメタロプロテアーゼ(MMP)遺伝子の発現が増加していた。MMP阻害剤は、in vitroでCDH1 KO hGO細胞およびSRCC細胞株の細胞運動を抑制した。95例の臨床胃癌組織を用いた免疫蛍光分析により、MMP-3はE-カドヘリン異常のSRCCに特異的に多く存在することが示された。また、CDH1 KO後、CXCR4分子が細胞膜上に移行した。CXCR4のリガンドであるCXCL12を培養液に添加すると、CDH1 KO hGO細胞の細胞生存率が延長し、CXCR4アンタゴニストであるAMD3100によってその効果が消失した。SRCCの臨床サンプルでは、CXCL12を分泌する線維芽細胞が癌領域に著しく浸潤していることを確認した。以上より、MMPとCXCL12/CXCR4軸は、E-カドヘリン欠損SRCCの新規治療標的として有望な候補であると考えられた。

  • Histological background of dedifferentiated solitary fibrous tumour. Invited Reviewed International journal

    Yamada Y, Kohashi K, Kinoshita I, Yamamoto H, Iwasaki T, Yoshimoto M, Ishihara S, Toda Y, Ito Y, Kuma Y, Yamada-Nozaki Y, Koga Y, Hashisako M, Kiyozawa D, Kitahara D, Narutomi F, Kuboyama Y, Nakamura T, Inoue T, Mukai M, Honda Y, Toyokawa G, Tsuchihashi K, Fushimi F, Taguchi K, Nishiyama K, Tamiya S, Oshiro Y, Furue M, Nakashima Y, Suzuki S, Iwaki T, Oda Y.

    J Clin Pathol.   75   397 - 403   2022.6

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

  • Decision making for anti-VEGF inhibitor continuation: dip stick? or urine protein/creatinine ratio? (VERSiON UP study). Reviewed International journal

    Nakamura M, Funakoshi T, Kataoka S, Horimatsu T, Nishikawa Y, Matsubara T, Mizukami T, Goto T, Tsuchihashi K, Baba E, Tsumura T, Mihara Y, Hamaguchi T, Yanagita M, Muto M.

    BMC Cancer.   22   515   2022.5

    　More details

    Language：Japanese   Publishing type：Research paper (scientific journal)  

  • 特集 希少がんに対する診療提供体制の現状と展望 地域における希少がん診療提供体制

    土橋 賢司, 馬場 英司

    医学のあゆみ   281 ( 4 )   305 - 309   2022.4   （ ISSN:00392359 ）

    　More details

    Publisher：医歯薬出版  

    DOI： 10.32118/ayu28104305

    CiNii Research

  • Myxoid type and non-myxoid type of intimal sarcoma in large vessels and heart: review of histological and genetic profiles of 20 cases Reviewed International journal

    Yamada Y, Kinoshita I, Miyazaki Y, Tateishi Y, Kuboyama Y, Iwasaki T, Kohashi K, Yamamoto H, Ishihara S, Toda Y, Ito Y, Susuki Y, Kawaguchi K, Hashisako M, Yamada-Nozaki Y, Kiyozawa D, Mori T, Yamamoto T, Tsuchihashi K, Kuriwaki K, Mukai M, Kawai M, Suzuki K, Nishimura H, Bando K, Masumoto J, Fukushima M, Motoshita J, Mori H, Shiose A, Oda Y

    Virchows Arch   480   919 - 925   2022.4

    　More details

    Language：Japanese   Publishing type：Research paper (scientific journal)  

  • Spontaneous Regression of Metachronous Intra-Abdominal Desmoid Tumor in a Patient with Familial Adenomatous Polyposis Reviewed International journal

    Tsuchihashi K, Yamaguchi K, Taguchi R, Kohashi K, Ijichi K, Okumura Y, Nakano M, Ohno A, Hioki T, Shimokawa H, Ariyama H, Kusaba H, Oda Y, Akashi K, Baba E.

    Case Rep Oncol   15   71 - 77   2022.2

    　More details

    Language：Japanese   Publishing type：Research paper (scientific journal)  

  • Nuclear translocation of IGF-1 receptor contributes to eribulin resistance in colorectal cancer

    Yoshihiro, T; Ariyama, H; Tsuchihashi, K; Isobe, T; Akashi, K; Baba, E

    CANCER SCIENCE   113   550 - 550   2022.2   （ ISSN:1347-9032 eISSN:1349-7006 ）

    　More details

  • Potential therapeutic targets discovery by transcriptome analysis of in vitro human gastric signet-ring carcinoma model

    Yamaguchi, K; Yoshihiro, T; Ariyama, H; Tsuchihashi, K; Kusaba, H; Baba, E; Akashi, K

    CANCER SCIENCE   113   2022.2   （ ISSN:1347-9032 eISSN:1349-7006 ）

    　More details

  • Improvement in recurring nivolumab-induced pneumonitis with repetitive administration of infliximab in a patient with head and neck cancer: A case report. Reviewed International journal

    Ueno S, Uenomachi M, Kusaba H, Ito M, Suzuki K, Ohmura H, Tsuchihashi K, Ariyama H, Akashi K, Baba E.

    Mol Clin Oncol.   15   221   2021.10

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

  • Does the Use of Peripheral Immune-Related Markers Indicate Whether to Administer Pazopanib, Trabectedin, or Eribulin to Advanced Soft Tissue Sarcoma Patients? Reviewed International journal

    Shimada E, Endo M, Matsumoto Y, Tsuchihashi K, Ito M, Kusaba H, Nabeshima A, Nawata T, Maekawa A, Matsunobu T, Setsu N, Fujiwara T, Iida K, Nakagawa M, Hirose T, Kanahori M, Oyama R, Isobe T, Ariyama H, Kohashi K, Yamamoto H, Oda Y, Iwamoto Y, Akashi K, Baba E, Nakashima Y.

    J Clin Med.   10   4972   2021.10

    　More details

    Language：Japanese   Publishing type：Research paper (scientific journal)  

  • Prominent PD-L1-positive M2 macrophage infiltration in gastric cancer with hyper-progression after anti-PD-1 therapy: A case report. Medicine (Baltimore). Reviewed International journal

    Yamaguchi K, Tsuchihashi K, Tsuji K, Kito Y, Tanoue K, Ohmura H, Ito M, Isobe T, Ariyama H, Kusaba H, Akashi K, Baba E.

    Medicine (Baltimore)   100   e25773   2021.5

    　More details

    Language：Japanese   Publishing type：Research paper (scientific journal)  

  • Predictive impact of C-reactive protein to albumin ratio for recurrent or metastatic head and neck squamous cell carcinoma receiving nivolumab. Invited Reviewed International journal

    Tanoue K, Tamura S, Kusaba H, Shinohara Y, Ito M, Tsuchihashi K, Shirakawa T, Otsuka T, Ohmura H, Isobe T, Ariyama H, Koreishi S, Matsushita Y, Shimokawa H, Tanaka R, Mitsugi K, Akashi K, Baba E.

    Sci Rep.   11   2741   2021.2

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

  • A phase II study of FOLFOXIRI plus bevacizumab as initial chemotherapy for patients with untreated metastatic colorectal cancer: TRICC1414 (BeTRI) Reviewed International journal

    Shinozaki K, Yamada T, Nasu J, Matsumoto T, Yuasa Y, Shiraishi T, Nagano H, Moriyama I, Fujiwara T, Miguchi M, Yoshida R, Nozaka K, Tanioka H, Nagasaka T, Kurisu Y, Kobayashi M, Tsuchihashi K, Inukai M, Kikuchi T, Nishina T

    Int J Clin Oncol.   2021.2

    　More details

    Language：Japanese   Publishing type：Research paper (scientific journal)  

    DOI： doi: 10.1007/s10147-020-01811-w.

  • RNA N6-methyladenosine demethylase FTO regulates PD-L1 expression in colon cancer cells Invited Reviewed International journal

    Tsuruta N, Tsuchihashi K, Ohmura H, Yamaguchi K, Ito M, Ariyama H, Kusaba H, Akashi K, Baba E.

    Biochemi Biophys Res Commun.   530   235 - 239   2020.9

    　More details

    Language：Japanese   Publishing type：Research paper (scientific journal)  

  • Exploratory retrospective study of risk factors for thromboembolism treated with multi-kinase inhibitor pazopanib or Lenvatinib. Reviewed International journal

    Nio K, Tsuchihashi K, Taguchi K, Yoshihiro T, Yamaguchi K, Ito M, Moriyama S, Fukata M, Fujiwara T, Setsu N, Endo M, Matsumoto Y, Nakashima Y, Wakasaki T, Yasumatsu R, Ariyama H, Kusaba H, Kishimoto J, Akashi K, Baba E.

    International Journal of Surgery Oncology   5   e89   2020.5

    　More details

    Language：Japanese   Publishing type：Research paper (scientific journal)  

  • Prognostic scores for evaluating the survival benefit of regorafenib or trifluridine/tipiracil in patients with metastatic colorectal cancer: an exploratory analysis of the REGOTAS study. Reviewed International journal

    Moriwaki T, Fukuoka S, Masuishi T, Takashima A, Kumekawa Y, Kajiwara T, Yamazaki K, Esaki T, Makiyama A, Denda T, Hatachi Y, Suto T, Sugimoto N, Enomoto M, Ishikawa T, Kashiwada T, Oki E, Komatsu Y, Tsuji A, Tsuchihashi K, Sakai D, Ueno H, Tamura T, Yamashita K, Shimada Y.

    Int J Clin Oncol.   25   614 - 621   2020.4

    　More details

    Language：Japanese   Publishing type：Research paper (scientific journal)  

  • Helper T cell-dominant tertiary lymphoid structures are associated with disease relapse of advanced colorectal cancer. Reviewed International journal

    Yamaguchi K, Ito M, Ohmura H, Hanamura F, Nakano M, Tsuchihashi K, Nagai S, Ariyama H, Kusaba H, Yamamoto H, Oda Y, Nakamura M, Akashi K, Baba E.

    Oncoimmunology.   9   1724763   2020.2

    　More details

    Language：Japanese   Publishing type：Research paper (scientific journal)  

  • Methylation of drug resistance-related genes in chemotherapy-sensitive Epstein-Barr virus-associated gastric cancer Reviewed International journal

    Ohmura H, Ito M, Uchino K, Okada C, Tanishima S, Yamada Y, Momosaki S, Komoda M, Kuwayama M, Yamaguchi K, Okumura Y, Nakano M, Tsuchihashi K, Isobe T, Ariyama H, Kusaba H, Oda Y, Akashi K, Baba E.

    FEBS Open Bio.   10   147 - 157   2020.1

    　More details

    Language：Japanese   Publishing type：Research paper (scientific journal)  

  • Clinicopathological review of solitary fibrous tumors: dedifferentiation is a major cause of patient death. Invited Reviewed International journal

    Yamada Y, Kohashi K, Kinoshita I, Yamamoto H, Iwasaki T, Yoshimoto M, Ishihara S, Toda Y, Itou Y, Koga Y, Hashisako M, Nozaki Y, Kiyozawa D, Kitahara D, Inoue T, Mukai M, Honda Y, Toyokawa G, Tsuchihashi K, Matsushita Y, Fushimi F, Taguchi K, Tamiya S, Oshiro Y, Furue M, Nakashima Y, Suzuki S, Iwaki T, Oda Y.

    Virchows Arch   475   467 - 477   2019.10

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

  • Atrial fibrillation observed in a patient with esophageal cancer treated with fluorouracil. Reviewed International journal

    Moriyama S, Yokoyama T, Irie K, Ito M, Tsuchihashi K, Fukata M, Kusaba H, Maruyama T, Akashi K.

    J Cardiol Cases   20   183 - 186   2019.8

    　More details

    Language：Japanese   Publishing type：Research paper (scientific journal)  

  • Efficacy and safety of ramucirumab plus modified FOLFIRI for metastatic colorectal cancer. Reviewed International journal

    Yoshihiro T, Kusaba H, Makiyama A, Kobayashi K, Uenomachi M, Ito M, Doi Y, Mitsugi K, Aikawa T, Takayoshi K, Esaki T, Shimokawa H, Tsuchihashi K, Ariyama H, Akashi K, Baba E.

    Int J Clin Oncol.   2019.5

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

  • Endothelial-Mesenchymal Transition Drives Expression of CD44 Variant and xCT in Pulmonary Hypertension. Reviewed International journal

    Isobe S, Kataoka M, Endo J, Moriyama H, Okazaki S, Tsuchihashi K, Katsumata Y, Yamamoto T, Shirakawa K, Yoshida N, Shimoda M, Chiba T, Masuko T, Hakamata Y, Kobayashi E, Saya H, Fukuda K, Sano M.

    Am J Respir Cell Mol Biol.   2019.5

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

  • Role of Predictive Value of the Modified Glasgow Prognostic Score for Later-line Chemotherapy in Patients With Metastatic Colorectal Cancer. Reviewed International journal

    Tsuchihashi K, Ito M, Moriwaki T, Fukuoka S, Taniguchi H, Takashima A, Kumekawa Y, Kajiwara T, Yamazaki K, Esaki T, Makiyama A, Denda T, Satake H, Suto T, Sugimoto N, Katsumata K, Ishikawa T, Kashiwada T, Oki E, Komatsu Y, Okuyama H, Sakai D, Ueno H, Tamura T, Yamashita K, Kishimoto J, Shimada Y, Baba E.

    Clin Colorectal Cancer.   2018.12

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

  • Epidermal growth factor receptor promotes glioma progression by regulating xCT and GluN2B-containing N-methyl-d-aspartate-sensitive glutamate receptor signaling. Reviewed International journal

    Suina K*, Tsuchihashi K*, Yamasaki J, Kamenori S, Shintani S, Hirata Y, Okazaki S, Sampetrean O, Baba E, Akashi K, Mitsuishi Y, Takahashi F, Takahashi K, Saya H, Nagano O. (* equally contributed)

    Cancer Sci.   2018.12

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

  • Epithelial-mesenchymal transition is activated in CD44-positive malignant ascites tumor cells of gastrointestinal cancer. Invited Reviewed International journal

    Nakano M, Ito M, Tanaka R, Ariyama H, Mitsugi K, Makiyama A, Uchino K, Esaki T, Tsuruta N, Hanamura F, Yamaguchi K, Okumura Y, Sagara K, Takayoshi K, Nio K, Tsuchihashi K, Tamura S, Shimokawa H, Arita S, Miyawaki K, Kusaba H, Akashi K, Baba E.

    Cancer Sci.   2018.11

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

  • Metastatic esophageal carcinosarcoma comprising neuroendocrine carcinoma, squamous cell carcinoma, and sarcoma: A case report. Reviewed International journal

    Tsuchihashi K, Arita S, Fujiwara M, Iwasaki K, Hirano A, Yoshihiro T, Nio K, Koga Y, Esaki M, Ariyama H, Kusaba H, Moriyama T, Ohuchida K, Nagai E, Nakamura M, Oda Y, Akashi K, Baba E.

    Medicine (Baltimore)   2018.10

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

  • The risk factors for oxaliplatin-induced peripheral sensory neuropathy and thrombocytopenia in advanced gastric cancer. Reviewed International journal

    Yamaguchi K, Kusaba H, Makiyama A, Mitsugi K, Uchino K, Tamura S, Shibata Y, Esaki T, Ito M, Takayoshi K, Tsuchihashi K, Arita S, Ariyama H, Akashi K, Baba E.

    Cancer Chemother Pharmacol   2018.10

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

  • Activation of central/effector memory T cells and T-helper 1 polarization in malignant melanoma patients treated with anti-programmed death-1 antibody. Reviewed International journal

    Yamaguchi K, Mishima K, Ohmura H, Hanamura F, Ito M, Nakano M, Tsuchihashi K, Ota SI, Wada N, Uchi H, Ariyama H, Kusaba H, Niiro H, Akashi K, Baba E.

    Cancer Sci.   2018.10

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

  • PD-1+ TIM-3+ T cells in malignant ascites predict prognosis of gastrointestinal cancer. Reviewed International journal

    Nakano M, Ito M, Tanaka R, Yamaguchi K, Ariyama H, Mitsugi K, Yoshihiro T, Ohmura H, Tsuruta N, Hanamura F, Sagara K, Okumura Y, Nio K, Tsuchihashi K, Arita S, Kusaba H, Akashi K, Baba E.

    Cancer Sci.   2018.9

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

  • Successful chemotherapeutic treatment for metastatic littoral cell angioma: A case report. Reviewed International journal

    Takayoshi K, Doi G, Tsuruta N, Yoshihiro T, Nio K, Tsuchihashi K, Ariyama H, Odawara J, Shimoda S, Kohashi K, Oda Y, Itoh S, Harimoto N, Maehara Y, Kusaba H, Akashi K, Baba E.

    Medicine (Baltimore)   2018.4

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

  • Development of a functional thyroid model based on an organoid culture system. Reviewed International journal

    Saito Y, Onishi N, Takami H, Seishima R, Inoue H, Hirata Y, Kameyama K, Tsuchihashi K, Sugihara E, Uchino S, Ito K, Kawakubo H, Takeuchi H, Kitagawa Y, Saya H, Nagano O.

    Biochem Biophys Res Commun.   2018.4

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

  • Metastatic esophageal cancer presenting as shock by injury of vagus nerve mimicking baroreceptor reflex: A case report. Invited Reviewed International journal

    Tsuchihashi K, Yoshihiro T, Aikawa T, Nio K, Takayoshi K, Yokoyama T, Fukata M, Arita S, Ariyama H, Shimizu Y, Yoshida Y, Torisu T, Esaki M, Odashiro K, Kusaba H, Akashi K, Baba E.

    Medicine (Baltimore)   2017.12

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

  • Phase 1 study of sulfasalazine and cisplatin for patients with CD44v-positive gastric cancer refractory to cisplatin (EPOC1407). Invited Reviewed International journal

    Shitara K, Doi T, Nagano O, Fukutani M, Hasegawa H, Nomura S, Sato A, Kuwata T, Asai K, Einaga Y, Tsuchihashi K, Suina K, Maeda Y, Saya H, Ohtsu A.

    Gastric Cancer   2017.11

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

  • Lingual alveolar soft part sarcoma responsive to pazopanib: A case report. Invited Reviewed International journal

    Yoshihiro T, Tsuchihashi K, Nio K, Arita S, Nakano T, Yasumatsu R, Jiroumaru R, Ariyama H, Kusaba H, Oda Y, Akashi K, Baba E.

    Medicine (Baltimore).   2017.11

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

  • CD44 variant-dependent regulation of redox balance in EGFR mutation-positive non-small cell lung cancer: A target for treatment. Invited Reviewed International journal

    Kawano Y, Iwama E, Tsuchihashi K, Shibahara D, Harada T, Tanaka K, Nagano O, Saya H, Nakanishi Y, Okamoto I.

    Lung Cancer   2017.11

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

  • Regorafenib-induced retinal and gastrointestinal hemorrhage in a metastatic colorectal cancer patient with liver dysfunction: A case report. Invited Reviewed International journal

    Tsuchihashi K, Shimokawa H, Takayoshi K, Nio K, Aikawa T, Matsushita Y, Wada I, Arita S, Ariyama H, Kusaba H, Sonoda KH, Akashi K, Baba E.

    Medicine (Baltimore)   2017.10

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

  • Phase I study of salazosulfapyridine in combination with cisplatin and pemetrexed for advanced non-small-cell lung cancer. Invited Reviewed International journal

    Otsubo K, Nosaki K, Imamura CK, Ogata H, Fujita A, Sakata S, Hirai F, Toyokawa G, Iwama E, Harada T, Seto T, Takenoyama M, Ozeki T, Mushiroda T, Inada M, Kishimoto J, Tsuchihashi K, Suina K, Nagano O, Saya H, Nakanishi Y, Okamoto I.

    Cancer Sci   2017.9

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

  • Suggestion of added value by bevacizumab to chemotherapy in patients with unresectable or recurrent small bowel cancer. Invited Reviewed International journal

    Takayoshi K, Kusaba H, Uenomachi M, Mitsugi K, Makiyama C, Makiyama A, Uchino K, Shirakawa T, Shibata Y, Shinohara Y, Inadomi K, Tsuchihashi K, Arita S, Ariyama H, Esaki T, Akashi K, Baba E.

    Cancer Chemother Pharmacol.   2017.8

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

  • Pancreatic acinar cell carcinoma presenting with panniculitis, successfully treated with FOLFIRINOX: A case report. Invited Reviewed International journal

    Yoshihiro T, Nio K, Tsuchihashi K, Ariyama H, Kohashi K, Tsuruta N, Hanamura F, Inadomi K, Ito M, Sagara K, Okumura Y, Nakano M, Arita S, Kusaba H, Oda Y, Akashi K, Baba E.

    Mol Clin Oncol   2017.6

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

  • Dose-escalation study for the targeting of CD44v+ cancer stem cells by sulfasalazine in patients with advanced gastric cancer (EPOC1205). Invited Reviewed International journal

    Shitara K, Doi T, Nagano O, Imamura CK, Ozeki T, Ishii Y, Tsuchihashi K, Takahashi S, Nakajima TE, Hironaka S, Fukutani M, Hasegawa H, Nomura S, Sato A, Einaga Y, Kuwata T, Saya H, Ohtsu A.

    Gastric Cancer   2017.5

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

  • Programmed death-ligand 1 expression is associated with fibrosarcomatous transformation of dermatofibrosarcoma protuberans. Invited Reviewed International journal

    Tsuchihashi K, Kusaba H, Yamada Y, Okumura Y, Shimokawa H, Komoda M, Uchino K, Yoshihiro T, Tsuruta N, Hanamura F, Inadomi K, Ito M, Sagara K, Nakano M, Nio K, Arita S, Ariyama H, Kohashi K, Tominaga R, Oda Y, Akashi K, Baba E.

    Mol Clin Oncol   2017.5

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

  • Cardiac metastasis of squamous cell carcinoma of the thyroid gland with severe disseminated intravascular coagulation: A case report. Invited Reviewed International journal

    Yoshihiro T, Tsuchihashi K, Kusaba H, Nakashima T, Obara T, Nio K, Takayoshi K, Kodama H, Tsuruta N, Kiyohara H, Asai K, Harada E, Kamezaki K, Arita T, Sato M, Yamamoto H, Arita S, Ariyama H, Odashiro K, Oda Y, Akashi K, Baba E.

    Mol Clin Oncol   2017.1

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

  • Current cigarette smoking is a reversible cause of elevated white blood cell count: Cross-sectional and longitudinal studies. Invited Reviewed International journal

    Higuchi T, Omata F, Tsuchihashi K, Higashioka K, Koyamada R, Okada S

    Prev Med Rep   2016.8

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

  • Eradication of CD44-variant positive population in head and neck tumors through controlled intracellular navigation of cisplatin-loaded nanomedicines. Invited Reviewed International journal

    Wang M, Miura Y, Tsuchihashi K, Miyano K, Nagano O, Yoshikawa M, Tanabe A, Makino J, Mochida Y, Nishiyama N, Saya H, Cabral H, Kataoka K.

    J Control Release   2016.5

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

  • Development of an ErbB4 monoclonal antibody that blocks neuregulin-1-induced ErbB4 activation in cancer cells. Invited Reviewed International journal

    Okazaki S, Nakatani F, Masuko K, Tsuchihashi K, Ueda S, Masuko T, Saya H, Nagano O.

    Biochem Biophys Res Commun   2016.1

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

  • Successful treatment of adult Langerhans cell histiocytosis with intensified chemotherapy. Invited Reviewed International journal

    Minami M, Shima T, Kato K, Yamamoto H, Tsuchihashi K, Oku S, Shimokawa T, Tochigi T, Yoshimoto G, Kamezaki K, Takenaka K, Iwasaki H, Oda Y, Miyamoto T, Akashi K.

    Int J Hematol.   2015.8

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

  • Impacts of CD44 knockdown in cancer cells on tumor and host metabolic systems revealed by quantitative imaging mass spectrometry. Invited Reviewed International journal

    Ohmura M, Hishiki T, Yamamoto T, Nakanishi T, Kubo A, Tsuchihashi K, Tamada M, Toue S, Kabe Y, Saya H, Suematsu M.

    Nitric Oxide   2015.4

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

  • Ink4a/Arf-Dependent Loss of Parietal Cells Induced by Oxidative Stress Promotes CD44-Dependent Gastric Tumorigenesis. Invited Reviewed International journal

    Seishima R, Wada T, Tsuchihashi K, Okazaki S, Yoshikawa M, Oshima H, Oshima M, Sato T, Hasegawa H, Kitagawa Y, Goldenring JR, Saya H, Nagano O.

    Cancer Prev Res (Phila)   2015.1

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

  • Interstitial pneumonia during bevacizumab-based chemotherapy for colorectal cancer. Invited Reviewed International journal

    Tamura S, Kusaba H, Kubo N, Ijichi K, Tsuchihashi K, Komoda M, Uchino K, Ariyama H, Akashi K, Baba E

    Med Oncol.   2014.3

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

  • Functional role of CD44v-xCT system in the development of spasmolytic polypeptide-expressing metaplasia. Invited Reviewed International journal

    Wada T, Ishimoto T, Seishima R, Tsuchihashi K, Yoshikawa M, Oshima H, Oshima M, Masuko T, Wright NA, Furuhashi S, Hirashima K, Baba H, Kitagawa Y, Saya H, Nagano O.

    Cancer Sci.   2013.10

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

  • Systemic chemotherapy for metastatic non-mucinous appendiceal adenocarcinoma: a case report and literature review Invited Reviewed International journal

    Kenji Tsuchihashi, Kotoe Takayoshi, Keita Uchino, Tsuyoshi Shirakawa, Hozumi Kumagai, Shingo Tamura, Masato Komoda, Taichi Isobe, Shigeo Takaishi, Hitoshi Kusaba, Shinichi Aishima, Koichi Akashi, Eishi Baba

    International Cancer Conference Journal   2013.1

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

▼display all

Presentations

  • Discussant: Rare cancer, Cancer of Unknown Primary Invited

    Kenji Tsuchihashi

    2023.2 

    　More details

    Event date： 2024.4

    Language：English  

    Country：Japan  

  • Survival outcomes of adult head and neck para-meningeal rhabdomyosarcoma: a multicenter retrospective study from Kyushu Medical Oncology Group (KMOG)

    Kenji Tsuchihashi, Mamoru Ito, Shuji Arita, Hitoshi Kusaba, Tatsuhiro Kajitani, Kotoe Oshima, Shingo Tamura, Tsuyoshi Shirakawa, Hozumi Shimokawa, Keita Uchino, Masato Komoda, Taishi Isobe, Hiroshi Ariyama, Taito Esaki, Miyoko Matsuo, Tadamasa Yoshitake, Yoshinao Oda, Koichi Akashi, Eishi Baba

    2024.2 

    　More details

    Event date： 2024.4

    Language：English  

    Country：Japan  

  • 肉腫をはじめとする希少がん診療ネットワーク構築・相談支援の取り組み Invited

    土橋賢司,　坂本節子,　遠藤誠,　馬場英司

    第７回サルコーマ治療研究学会学術集会  2024.2 

    　More details

    Event date： 2024.4

    Language：Japanese   Presentation type：Symposium, workshop panel (public)  

    Country：Japan  

  • Esophageal cancer shows spontaneous plasticity between epithelial and mesenchymal status International conference

    Kenji Tsuchihashi , Yuki Hirata , Juntaro Yamasaki , Kentaro Suina , Kenro Tanoue , Toshifumi Yae , Kenta Masuda , Eishi Baba , Koichi Akashi , Yuko Kitagawa , Hideyuki Saya , Osamu Nagano

    AACR Annual Meeting 2023  2023.4 

    　More details

    Event date： 2024.4

    Language：English  

    Country：Japan  

  • PD-L1 expression is regulated by RNA N6-methyladenosine demethylase FTO in colon cancer cells

    Kenji Tsuchihashi, Nobuhiro Tsuruta, Hirofumi Ohmura, Kyoko Yamaguchi, Mamoru Ito, kenro Tanoue, Taichi Isobe, Hiroshi Ariyama, Hitoshi Kusaba, Koichi Akashi, Eishi Baba

    2021.6 

    　More details

    Event date： 2022.6

    Language：English  

    Country：Japan  

  • Eribulin as a first-line treatment for patients with advanced soft tissue sarcoma:a retrospective study

    Kenji Tsuchihashi, Tomoyasu Yoshihiro, Toshifumi Fujiwara, Nokitaka Setsu, Makoto Endo, Yoshihiro Matsumoto, Masato Uenomachi, Mamoru Ito, Kohei Arimizu, Hirofumi Omura, Nobuhiro Tsuruta, Fumiyasu Hanamura, Kyoko Yamaguchi, Taichi Isobe, Hiroshi Ariyama, Hitoshi Kusaba, Koichi Akashi, Eishi Baba

    2019.7 

    　More details

    Event date： 2020.6

    Language：English   Presentation type：Oral presentation (general)  

    Country：Japan  

  • Incidence of thromboembolism in patients treated with mutiple kinase inhibitors: a retrospective study

    Kenji Tsuchihashi, Kenta Nio, Ryosuke Taguchi, Tomoyasu Yoshihiro, Kyoko Yamaguchi, Shohei Moriyama, Mitsuhiro Fukata, Toshifumi Fujiwara, Nokitaka Setsu, Makoto Endo, Yoshihiro Matsumoto, Moe Kondo, Koki Uehara, Shohei Ueno, Masato Uenomachi, Mamoru Ito, Hiroshi Ariyama, Hitoshi Kusaba, Koichi Akashi, Eishi Baba

    2019.7 

    　More details

    Event date： 2020.6

    Language：English   Presentation type：Oral presentation (general)  

    Country：Japan  

  • 腫瘍内科医の視点からのクリニカルクエスチョンとその背景

    土橋賢司, 赤司浩一,馬場英司

    がん関連三学会Rising Starネットワーキング  2024.1 

    　More details

    Event date： 2024.4

    Language：Japanese  

    Venue：横浜   Country：Japan  

  • 成人希少固形腫瘍の診療の実際とがんゲノムを中心とした治療開発状況 Invited

    土橋賢司

    小児血液・がんセミナー in 九州山口  2024.1 

    　More details

    Event date： 2024.4

    Language：Japanese   Presentation type：Oral presentation (general)  

    Venue：福岡   Country：Japan  

  • A phase 2 trial of nivolumab monotherapy in rare cancer patients with mismatch repair deficiency or MSI-high: ROCK Trial (NCCH1709) a MASTER KEY sub-study

    Kenji Tsuchihashi, Hitomi Sumiyoshi Okuma, Ryunosuke Machida, Ryo Sadachi, Akihiro Hirakawa, Hiroshi Ariyama, Masashi Kanai, Masahisa Kamikura, Kenta Anjo, Akari Hiramitsu, Keisuke Watanabe, Shigeki Sekine, Natsuko Okita, Kenichi Nakamura, Kan Yonemori

    2023.3 

    　More details

    Event date： 2023.3

    Language：English   Presentation type：Oral presentation (general)  

    Country：Japan  

  • 成人頭頚部傍髄膜横紋筋肉腫の治療成績

    土橋賢司　伊東守　在田修二　草場仁志　磯部大地　有山寛　橋本和樹　吉武忠正　小田義直　赤司浩一　馬場英司

    第6回日本サルコーマ治療研究学会学術集会  2023.2 

    　More details

    Event date： 2023.2

    Language：Japanese   Presentation type：Oral presentation (general)  

    Country：Japan  

  • Presence and its role of spontaneous epithelial-mesenchymal plasticity in esophageal cancer

    Kenji Tsuchihashi, Yuki Hirata, Juntaro Yamasaki, Kentaro Suina, Kenro Tanoue, Toshifumi Yae, Kenta Masuda, Eishi Baba, Koichi Akashi, Yuko Kitagawa, Hideyuki Saya, Osamu Nagano

    2022.9 

    　More details

    Event date： 2022.9

    Language：Japanese   Presentation type：Oral presentation (general)  

    Country：Japan  

  • HER2胃癌の現状と最新情報

    土橋賢司

    第5回 FLAG Meeting  2021.5 

    　More details

    Event date： 2022.6

    Language：Japanese  

    Country：Japan  

  • 食道癌におけるCD44発現に特徴づけられる上皮間葉転換の自然可塑性モデル

    土橋 賢司, 山崎 淳太郎, 推名 健太郎, 馬場 英司, 赤司 浩一, 佐谷 秀行, 永野 修

    第19回 日本臨床腫瘍学会学術集会  2022.2 

    　More details

    Event date： 2022.6

    Language：Japanese  

    Country：Japan  

  • がんプロにおける希少がんの教育　現況と課題

    土橋賢司

    全国がんプロ合同教育フォーラム  2021.2 

    　More details

    Event date： 2021.2

    Language：Japanese  

    Country：Japan  

  • 希少がん治療の現状と今後の展望

    土橋賢司

    令和２年度第１回 がんプロセミナー  2020.10 

    　More details

    Event date： 2020.10

    Language：Japanese  

    Country：Japan  

  • 進行再発大腸癌治療における薬物療法の現状と最近の話題

    土橋賢司

    佐賀県病院薬剤師会　第11回オンコロジー研修会  2019.11 

    　More details

    Event date： 2020.6

    Language：Japanese   Presentation type：Oral presentation (general)  

    Country：Japan  

  • 甲状腺癌における分子標的薬のエビデンスと使用の工夫

    土橋賢司

    2019.9 

    　More details

    Event date： 2020.6

    Language：Japanese   Presentation type：Oral presentation (general)  

    Venue：福岡   Country：Japan  

  • がん患者の腹部膨満の原因

    土橋賢司

    第4回日本がんサポーティブケア学会  2019.9 

    　More details

    Event date： 2020.6

    Language：Japanese   Presentation type：Oral presentation (general)  

    Venue：青森   Country：Japan  

  • 希少がんの現状と治療開発

    土橋賢司

    第59回九州大学病院がんセミナー  2019.11 

    　More details

    Event date： 2019.11

    Language：Japanese  

    Country：Japan  

  • 消化管神経内分泌腫瘍の薬物療法

    土橋賢司

    神経内分泌腫瘍セミナーin福岡  2019.11 

    　More details

    Event date： 2019.11 - 2020.6

    Language：Japanese   Presentation type：Oral presentation (general)  

    Country：Japan  

  • 病変間で経過の異なる家族性大腸腺腫症に合併した腹腔内デスモイド腫瘍の１例

    土橋賢司、草場仁志、山口享子、伊東守、正月泰士、伊地知佳世、孝橋賢一、有山寛、小田義直、赤司浩一、馬場英司

    第２回日本サルコーマ治療研究学会学術集会  2019.2 

    　More details

    Event date： 2019.6

    Language：Japanese  

    Country：Japan  

  • 大腸がんの術後補助化学療法の選択について

    土橋賢司

    第12回　宮崎がん治療フロンティア  2018.6 

    　More details

    Event date： 2019.6

    Language：Japanese  

    Country：Japan  

  • Predictive value of the modified Glasgow Prognostic Score for later-line chemotherapy in metastatic colorectal cancer

    Kenji Tsuchihashi, Mamoru Ito, Toshikazu Moriwaki, Shota Fukuoka, Hiroya Taniguchi, Atsuo Takashima, Yosuke Kumekawa, Takeshi Kajiwara, Kentaro Yamazaki, Tomomi Aikawa, Akitaka Makiyama, Tadamichi Denda, Junji Kishimoto, Yasuhiro Shimada, Eishi Baba

    2018.7 

    　More details

    Event date： 2019.6

    Language：Japanese   Presentation type：Oral presentation (general)  

    Country：Japan  

  • 脳腫瘍に対する酸化ストレス回避機構を標的にした治療法の開発

    土橋賢司、岡崎章吾、大村光代、サンペトラオルテア、大西伸幸、益子高、馬場英司、赤司浩一、佐谷秀行、永野修

    第15回　日本臨床腫瘍学会学術集会  2017.7 

    　More details

    Event date： 2018.6

    Language：Japanese   Presentation type：Oral presentation (general)  

    Country：Japan  

  • xCT promotes malignant phenotypes in EGFR-expressing glioma International conference

    Tsuchihashi K, Okazaki S, Yoshikawa M, Seishima R, Sampetrean O, Onishi N, Wakimoto H, Furnari F, Baba E, Akashi K, Saya H, Nagano O

    AACR Annual Meeting 2017  2017.4 

    　More details

    Event date： 2018.6

    Language：English  

    Country：United States  

  • リンパ節転移による頸胸部交感神経幹・迷走神経障害により神経原性ショックを呈した食道癌の一例

    土橋賢司、在田修二、吉弘知恭、二尾健太、高吉琴絵、有山寛、草場仁志、赤司浩一、馬場英司

    第22回　日本緩和医療学会学術集会  2017.6 

    　More details

    Event date： 2018.6

    Language：Japanese  

    Country：Japan  

  • 神経内分泌癌並びに扁平上皮癌を上皮成分とする転移性食道癌肉腫に対してCDDP/VP-16療法を行って完全奏効を得た1例

    土橋賢司、在田修二、二尾健太、平野敦士、古賀裕、平橋美奈子、有山寛、草場仁志、小田義直、馬場英司

    第15回　日本臨床腫瘍学会学術集会  2017.7 

    　More details

    Event date： 2018.6

    Language：Japanese  

    Country：Japan  

  • 当院におけるTS-1、ロンサーフの位置づけ

    土橋　賢司

    第21回 Cross talk with the Pharmacists  2016.12 

    　More details

    Event date： 2016.12

    Language：Japanese  

    Venue：九州大学医学部   Country：Japan  

  • DICを契機に診断された甲状腺扁平上皮癌心転移に対して化学放射線療法を施行した一例

    土橋賢司、吉弘知恭、二尾健太、草場仁志、在田修二、有山寛、佐藤方宣、小田義直,　馬場英司

    第７９回　福岡がん化学療法研究会  2016.11 

    　More details

    Event date： 2016.11

    Language：Japanese   Presentation type：Oral presentation (general)  

    Venue：福岡センタービル   Country：Japan  

  • The EGF receptor promotes the malignant potential of glioma by regulating amino acid transport system xc(–)

    土橋賢司、永野修、岡崎章悟、大村光代、サンペトラオルテア、吉川桃子、清島亮、大西伸幸、益子高、末松誠、馬場英司、赤司浩一、佐谷秀行

    第75回　日本癌学会学術総会  2016.10 

    　More details

    Event date： 2016.10 - 2018.6

    Language：Japanese   Presentation type：Oral presentation (general)  

    Country：Japan  

  • Posterior mediatinal tumor as an usual metastasis of dermatofibrosarcoma protuberance of dermatofibrosarcoma protuberance

    2016.7 

    　More details

    Event date： 2016.7

    Language：Japanese  

    Country：Japan  

  • 悪性孤立性線維性腫瘍の病態と治療

    土橋賢司、草場仁志、高吉琴絵、稲富享子、中野倫孝、奥村祐太、田中守、鶴田展大、相川智美、相良浩輔、二尾健太、在田修二、有山寛、山田裕一、孝橋賢一、小田義直、馬場英司

    第77回福岡がん化学療法研究会  2016.3 

    　More details

    Event date： 2016.3

    Language：Japanese   Presentation type：Oral presentation (general)  

    Country：Japan  

  • 食道癌における自然な上皮間葉転換可塑性の存在とその意義(Presence and its role of spontaneous epithelial-mesenchymal plasticity in esophageal cancer)

    土橋 賢司, 平田 雄紀, 山崎 淳太郎, 推名 健太郎, 田ノ上 絢郎, 八戸 敏文, 増田 健太, 馬場 英司, 赤司 浩一, 北川 雄光, 佐谷 秀行, 永野 修

    日本癌学会総会記事  2022.9  (一社)日本癌学会

    　More details

    Language：English  

  • 食道がんにおける免疫療法の潜在的な標的としてCD39+CD8+T細胞は空間的、表現型的に異なるフェノタイプから構成される(Spatially and phenotypically distinct CD39+CD8+Tcells as potential target of immunotherapy in esophageal cancer)

    田ノ上 絢郎, 大村 洋文, 篠原 雄大, 上原 康輝, 伊東 守, 山口 享子, 土橋 賢司, 田村 真吾, 下川 穂積, 磯部 大地, 有山 寛, 柴田 義宏, 三ツ木 健二, 江崎 泰斗, 赤司 浩一, 馬場 英司

    日本癌学会総会記事  2023.9  (一社)日本癌学会

    　More details

    Language：English  

  • 限局型食道扁平上皮癌に対するFOLFOXを用いた根治的化学放射線療法の後方視的観察研究

    山本 祥之, 杉山 圭司, 白石 和寛, 下嵜 啓太郎, 岡田 真央, 山本 駿, 松原 裕樹, 古田 光寛, 廣瀬 優, 土橋 賢司, 高橋 直樹, 町田 望, 筑木 隆雄, 吉井 貴子, 平田 賢郎

    日本癌治療学会学術集会抄録集  2022.10  (一社)日本癌治療学会

    　More details

    Language：English  

  • 進行食道扁平上皮癌に対するFOLFOXを用いた緩和的化学放射線療法

    岡田 真央, 杉山 圭司, 白石 和寛, 下嵜 啓太郎, 山本 駿, 松原 裕樹, 古田 光寛, 廣瀬 優, 小森 梓, 土橋 賢司, 舛石 俊樹, 山本 祥之, 筑木 隆雄, 平田 賢郎

    日本癌治療学会学術集会抄録集  2022.10  (一社)日本癌治療学会

    　More details

    Language：English  

  • 胃癌発癌モデルを用いた遺伝子発現解析に基づく胃印環細胞癌の新規治療標的の探索(Potential therapeutic targets discovery by transcriptome analysis of signet ring carcinoma model)

    山口 享子, 吉弘 知恭, 有山 寛, 土橋 賢司, 草場 仁志, 赤司 浩一, 馬場 英司

    日本胃癌学会総会記事  2022.3  (一社)日本胃癌学会

    　More details

    Language：English  

  • 癌ゲノム医療の成果と課題　九州大学病院がんエキスパートパネルにおける消化器悪性腫瘍のがんゲノム検査の現状とC-CATデータを用いた研究について

    磯部 大地, 伊東 守, 山口 享子, 上野 翔平, 土橋 賢司, 馬場 英司

    日本消化器病学会雑誌  2024.3  (一財)日本消化器病学会

    　More details

    Language：Japanese  

  • 消化器領域におけるがん免疫療法の現状と課題　ニボルマブ治療を受けた切除不能進行食道癌患者における末梢血中の疲弊細胞の意義

    田ノ上 絢郎, 大村 洋文, 土橋 賢司, 篠原 雄大, 伊東 守, 山口 享子, 田村 真吾, 下川 穂積, 磯部 大地, 柴田 義宏, 有山 寛, 田中 吏佐, 草場 仁志, 江崎 泰斗, 三ツ木 健二, 赤司 浩一, 馬場 英司

    日本消化器病学会九州支部例会・日本消化器内視鏡学会九州支部例会プログラム・抄録集  2022.6  日本消化器病学会-九州支部

    　More details

    Language：Japanese  

  • 悪性軟部腫瘍の希少性と多様性に対して、われわれはどう対峙すべきか　多職種連携の重要性と地域希少がんセンターに求められる役割

    遠藤 誠, 松本 嘉寛, 土橋 賢司, 馬場 英司, 中島 康晴

    日本整形外科学会雑誌  2022.6  (公社)日本整形外科学会

    　More details

    Language：Japanese  

  • 希少がんの治療戦略　信頼と絆に基づく肉腫のチーム医療

    遠藤 誠, 土橋 賢司, 松本 嘉寛, 坂本 節子, 鍋島 央, 飯田 圭一郎, 藤原 稔史, 伊東 守, 磯部 大地, 有山 寛, 赤司 浩一, 馬場 英司, 中島 康晴

    日本癌治療学会学術集会抄録集  2022.10  (一社)日本癌治療学会

    　More details

    Language：English  

  • 切除不能食道扁平上皮癌におけるFOLFOX療法に関する多施設後ろ向き観察研究

    白石 和寛, 杉山 圭司, 下嵜 啓太郎, 岡田 真央, 松原 裕樹, 廣瀬 優, 土橋 賢司, 舛石 俊樹, 平田 賢郎

    日本食道学会学術集会プログラム・抄録集  2023.6  (NPO)日本食道学会

    　More details

    Language：English  

  • 免疫チェックポイント阻害薬併用療法によるB細胞の分化と抗腫瘍効果ならびに有害事象との関連性について(B cell differentiation by combined immune checkpoint blockade is associated with tumor suppression and adverse events)

    上原 康輝, 田ノ上 絢郎, 山口 享子, 大村 洋文, 伊東 守, 土橋 賢司, 田村 真吾, 磯部 大地, 山元 英崇, 小田 義直, 赤司 浩一, 馬場 英司

    日本癌学会総会記事  2023.9  (一社)日本癌学会

    　More details

    Language：English  

  • 九州の基礎・臨床研究:腫瘍免疫・自己免疫・ゲノム　消化器がんの腫瘍免疫における上皮間葉転換、エピトランスクリプトームの関わりと今後の展望

    土橋 賢司, 馬場 英司

    日本消化器病学会九州支部例会・日本消化器内視鏡学会九州支部例会プログラム・抄録集  2023.5  日本消化器病学会-九州支部

    　More details

    Language：Japanese  

  • TPX2の増幅は大腸癌細胞株におけるオキサリプラチン感受性の潜在的なバイオマーカーとなる(The amplification of TPX2 is a potential biomarker of oxaliplatin-susceptibility in colorectal cancer)

    上野 翔平, 磯部 大地, 田口 綾祐, 土橋 賢司, 有山 寛, 赤司 浩一, 馬場 英司

    日本癌学会総会記事  2022.9  (一社)日本癌学会

    　More details

    Language：English  

  • TPX2の増幅はCINフェノタイプの大腸癌のオキサリプラチン感受性のバイオマーカーである(TPX2-amplified is a biomarker of oxaliplatin-sensitivity of colorectal cancers(CRCs) with CIN phenotype)

    上野 翔平, 磯部 大地, 田口 綾祐, 土橋 賢司, 赤司 浩一, 馬場 英司

    日本癌学会総会記事  2023.9  (一社)日本癌学会

    　More details

    Language：English  

  • DNMT3Bは患者由来の左側大腸癌オルガノイド形成能を維持する(DNMI3B maintains the organoid-formation ability of left-sided colorectal cancer derived from patients)

    田口 綾祐, 磯部 大地, 上野 翔平, 菊繁 吉謙, 土橋 賢司, 有山 寛, 赤司 浩一, 馬場 英司

    日本癌学会総会記事  2022.9  (一社)日本癌学会

    　More details

    Language：English  

▼display all

MISC

  • Epithelioid hemangioendothelioma-its history, clinical features, molecular biology and current therapy(タイトル和訳中)

    Tsuchihashi Kenji, Baba Eishi

    Japanese Journal of Clinical Oncology   54 ( 7 )   739 - 747   2024.7   （ ISSN:0368-2811 ）

    　More details

    Language：English   Publisher：Oxford University Press  

  • オンコロジストのためのSNSの活用方法

    扇屋 大輔, 後藤 知之, 高見澤 重賢, 上原 悠治, 岡野 尚弘, 尾崎 由記範, 木澤 莉香, 近藤 千紘, 土橋 賢司, 山口 祐平, 寺田 満雄

    腫瘍内科   33 ( 2 )   176 - 182   2024.2   （ ISSN:1881-6568 ）

    　More details

    Language：Japanese   Publisher：(有)科学評論社  

  • 希少がん入門(第79回)　九州地方における希少がん診療の現状と今後の展望

    土橋 賢司, 坂本 節子, 遠藤 誠, 馬場 英司

    Clinic Magazine   50 ( 3 )   28 - 29   2023.5   （ ISSN:0389-7451 ）

    　More details

    Language：Japanese   Publisher：(株)ドラッグマガジン  

  • 心腫瘤の診断のためのsheath-wedged吸引生検(Sheath-wedged Aspiration Biopsy for the Diagnosis of a Cardiac Mass)

    Moriyama Shohei, Yokoyama Taku, Tsuchihashi Kenji, Fukata Mitsuhiro

    Internal Medicine   61 ( 19 )   2987 - 2988   2022.10   （ ISSN:0918-2918 ）

    　More details

    Language：English   Publisher：(一社)日本内科学会  

  • 地域における希少がん診療提供体制――九州の場合 Reviewed

    土橋賢司　馬場英司

    医学のあゆみ   2022.4

    　More details

    Language：Japanese   Publishing type：Article, review, commentary, editorial, etc. (scientific journal)  

  • 【希少がんに対する診療提供体制の現状と展望】地域における希少がん診療提供体制　九州の場合

    土橋 賢司, 馬場 英司

    医学のあゆみ   281 ( 4 )   305 - 309   2022.4   （ ISSN:0039-2359 ）

    　More details

    Language：Japanese   Publisher：医歯薬出版(株)  

    希少がん診療体制の構築は、がん医療の重要課題である。国立がん研究センター中央病病院の希少がんセンター、希少がんホットラインに続き、大阪国際がんセンターや九州大学病院でもこれらが設置された。がんゲノム医療の拡大により医療機関間での希少がん患者の紹介が増えている傾向はあるが、当院の希少がんホットラインの相談状況やMASTER KEYプロジェクト登録者状況からは、九州地方での希少がん診療ネットワーク構築のニーズが浮かび上がる。また、希少がん診療はがんゲノム医療の対象となる前、とくに診断の段階から医療連携体制の構築が必要である。当院希少がんセンターは、各病院と連携していきながら九州地方の実情に沿った実用性のある希少がん診療ネットワーク構築を目指す。(著者抄録)

  • 希少がん診療の課題　大学病院から見て

    土橋賢司　馬場英司

    日本臨牀　増刊号　希少がん   2021.3

    　More details

    Language：Japanese   Publishing type：Article, review, commentary, editorial, etc. (scientific journal)  

  • がん患者の腹部膨満の原因と治療

    土橋賢司　馬場英司

    新薬と臨牀   2020.4

    　More details

    Language：Japanese   Publishing type：Article, review, commentary, editorial, etc. (scientific journal)  

  • 医薬品副作用学（第3版）　II 薬効別副作用 　4. 抗がん薬（３）分子標的薬　２）抗体製剤

    土橋賢司、馬場英司

    2019.6

    　More details

    Language：Japanese   Publishing type：Article, review, commentary, editorial, etc. (scientific journal)  

  • 胃癌薬物療法に関するガイドライン改訂のポイントと今後の展望

    馬場英司、土橋賢司

    2018.12

    　More details

    Language：Japanese   Publishing type：Article, review, commentary, editorial, etc. (scientific journal)  

  • 胃癌薬物療法に関するガイドライン改訂のポイントと今後の展望 Reviewed

    土橋賢司　馬場英司

    Approach to Oncology 特集 胃癌治療の現状と展望   2018.10

    　More details

    Language：Japanese   Publishing type：Article, review, commentary, editorial, etc. (scientific journal)  

  • 胃癌

    土橋賢司、有山寛、馬場英司

    がん転移学（下）：日本臨床　増刊   2017.12

    　More details

    Language：Japanese   Publishing type：Article, review, commentary, editorial, etc. (scientific journal)  

  • 胃がんの臨床的概論

    柴田義宏、土橋賢司、馬場英司

    2017.10

    　More details

    Language：Japanese   Publishing type：Article, review, commentary, editorial, etc. (scientific journal)  

  • スルファサラジンの基礎から臨床への橋渡し

    土橋賢司、永野修、佐谷秀行

    実験医学   2015.1

    　More details

    Language：Japanese   Publishing type：Article, review, commentary, editorial, etc. (scientific journal)  

  • がん幹細胞を標的とした治療薬開発の現状と課題

    土橋賢司、永野修、赤司浩一、佐谷秀行

    2014.3

    　More details

    Language：Japanese   Publishing type：Article, review, commentary, editorial, etc. (scientific journal)  

  • Cancer stem cellを標的とした治療薬開発 Reviewed

    土橋賢司、永野修、佐谷秀行

    腫瘍内科   2011.10

    　More details

    Language：Japanese   Publishing type：Article, review, commentary, editorial, etc. (scientific journal)  

▼display all

Industrial property rights

Patent   Number of applications: 1   Number of registrations: 1
Utility model   Number of applications: 0   Number of registrations: 0
Design   Number of applications: 0   Number of registrations: 0
Trademark   Number of applications: 0   Number of registrations: 0

Professional Memberships

  • 日本消化器病学会

  • 日本癌治療学会

  • 日本レックリングハウゼン病学会

  • 日本サルコーマ治療研究学会

  • 日本癌学会

  • 日本緩和医療学会

  • 日本臨床腫瘍学会

  • American Association for Cancer Research (AACR)

  • European Society for Medical ncology (ESMO)

▼display all

Committee Memberships

  • 日本臨床腫瘍学会   保険委員   Domestic

    2022.3 - Present   

  • 日本臨床腫瘍学会   協議員   Domestic

    2022.3 - 2026.2   

Academic Activities

  • 司会　セッション名：Mini Oral Session 21 セッションテーマ：TR・臨床薬理 1（基礎医学）

    第21回日本臨床腫瘍学会学術集会  （ 名古屋 ） 2024.2

    　More details

    Type：Competition, symposium, etc. 

  • 司会

    第19回 日本臨床腫瘍学会学術集会 Mini-Oral Session 41 消化器３（大腸１）  2022.2

    　More details

    Type：Competition, symposium, etc. 

  • 司会

    2021.11 - 2022.6

    　More details

    Type：Competition, symposium, etc. 

  • G-CSF適正使用ガイドライン

    2020.12 - 2022.12

    　More details

    Type：Academic society, research group, etc. 

  • 講師

    日本臨床腫瘍学会 第35回教育セミナー Aセッション  （ パシフィコ横浜（録画配信） ） 2020.3

    　More details

    Type：Competition, symposium, etc. 

  • チューター

    第17回日本臨床腫瘍学会学術集会　腫瘍内科セミナー  （ 横浜 ） 2019.7

    　More details

    Type：Competition, symposium, etc. 

  • 会長特別企画　がんゲノム医療時代に役立つ、ゲノム診断・橋渡し研究データの解釈のための基礎講義　司会

    第17回日本臨床腫瘍学会学術集会  （ パシフィコ横浜 ） 2019.7

    　More details

    Type：Competition, symposium, etc. 

  • ポスターセッション TR5　司会

    第17回日本臨床腫瘍学会学術集会  （ パシフィコ横浜 ） 2019.7

    　More details

    Type：Competition, symposium, etc. 

  • 講師

    日本臨床腫瘍学会　第33回教育セミナー Aセッション「腫瘍生物学II」  2019.3 - 2019.6

    　More details

    Type：Competition, symposium, etc. 

  • プロジェクトサポートメンバー

    2018.8

    　More details

    Type：Competition, symposium, etc. 

  • 重篤副作用疾患別対応マニュアル「手足症候群」

    2018.5 - 2019.6

    　More details

    Type：Academic society, research group, etc. 

  • ファシリテーター

    第15回日本臨床腫瘍学会学術集会　医学生・研修医のための腫瘍内科セミナー  （ 神戸国際会議場 ） 2017.7

    　More details

    Type：Competition, symposium, etc. 

  • 発熱性好中球減少症(FN)診療ガイドライン(改訂第2版)

    2016.4 - 2017.7

    　More details

    Type：Academic society, research group, etc. 

▼display all

Research Projects

  • がんのエピトランスクリプトームにより制御される免疫逃避機構の解明

    Grant number：20K07638  2020 - 2022

    日本学術振興会  科学研究費助成事業  基盤研究(C)

    　 More details

    Authorship：Principal investigator  Grant type：Scientific research funding

  • RNA修飾による消化器がんの免疫逃避機構の解明

    2020 - 2021

    新日本先進医療研究財団 研究助成金

    　 More details

    Authorship：Principal investigator  Grant type：Contract research

  • xCT発現がん幹細胞におけるグルタミン酸関連特性の包括的解明

    Grant number：18K15215  2018 - 2019

    日本学術振興会  科学研究費助成事業  若手研究

    　 More details

    Authorship：Principal investigator  Grant type：Scientific research funding

  • 頭頚部癌幹細胞におけるエピトランスクリプトームの機能解

    2018 - 2019

    新日本先進医療研究財団　研究助成金

    　 More details

    Authorship：Principal investigator  Grant type：Contract research

  • グルタミン酸受容体を標的としたがん幹細胞の新規治療法の開発

    2017 - 2019

    福岡県すこやか健康事業団　がん研究助成金

    　 More details

    Authorship：Principal investigator  Grant type：Contract research

  • 脳腫瘍の酸化ストレス抵抗性を打破する新規治療法の開発

    Grant number：16K18454  2016 - 2018

    日本学術振興会  科学研究費助成事業  若手研究

    　 More details

    Authorship：Principal investigator  Grant type：Scientific research funding

  • エピジェネティクス制御による転移性癌の新規治療法開発

    2013 - 2015

    日本学術振興会  特別研究員

    　 More details

    Grant type：Joint research

▼display all

Class subject

  • がん治療総論　支持療法総論

    2023.4 - 2023.9   First semester

  • 臨床腫瘍学の基本　シグナル伝達とがん遺伝子

    2023.4 - 2023.9   First semester

  • 小児・AYA世代を含むライフステージに応じたがん医療　ライフステージに応じた予防と栄養の役割

    2023.4 - 2023.9   First semester

  • 臨床腫瘍学の基本　シグナル伝達とがん遺伝子

    2022.4 - 2022.9   First semester

  • がん治療総論　支持療法総論

    2022.4 - 2022.9   First semester

  • 小児・AYA世代を含むライフステージに応じたがん医療　ライフステージに応じた予防と栄養の役割

    2022.4 - 2022.9   First semester

  • 臨床腫瘍学の基本　シグナル伝達とがん遺伝子

    2021.4 - 2021.9   First semester

  • 小児・AYA世代を含むライフステージに応じたがん医療　ライフステージに応じた予防と栄養の役割

    2021.4 - 2021.9   First semester

  • がん治療総論　支持療法総論

    2021.4 - 2021.9   First semester

▼display all

FD Participation

  • 2023.8   Role：Participation   Title：臨床実習後OSCE 評価者

  • 2022.9   Role：Participation   Title：共用試験臨床実習前OSCE 評価者

  • 2019.11   Role：Participation   Title：共用試験OSCE 評価者

  • 2019.10   Role：Participation   Title：共用試験OSCE内部評価者講習会

  • 2019.8   Role：Participation   Title：共用試験ＯＳＣＥ評価者認定講習会

  • 2018.11   Role：Participation   Title：共用試験OSCE内部評価者講習会

  • 2018.11   Role：Participation   Title：共用試験OSCE 評価者

  • 2017.11   Role：Participation   Title：共用試験OSCE内部評価者講習会

▼display all

Other educational activity and Special note

  • 2019  Special Affairs 

Social Activities

  • 第３回　クローバー会　希少治療の最前線

    九州大学病院　がんセンター  2021.10

    　More details

    Audience： General,　Scientific,　Company,　Civic organization,　Governmental agency

    Type：Seminar, workshop

Specialized clinical area

  • Other

    内科系/腫瘍内科学

Clinician qualification

  • Specialist

    The Japanese Society of Internal Medicine（JSIM）

  • Specialist

    Japanese Society of Medical Oncology（JSMO）

  • Specialist

    The Japanese Society of Gastroenterology（JSGE）

Year of medical license acquisition

  • 2008